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Production of mutant biological molecules for understanding biological principles or as 
therapeutic agents has gained considerable interest recently. Synthetic genes are today being 
widely used for production of such molecules due to the substantial decrease in the costs 
associated with gene synthesis technology. Along one such line, we have engineered tRNA 
genes in order to dissect the effects of G:U base-pairs on the accuracy of the protein translation 
machinery. Our results provide greater detail into the thermodynamic interactions between tRNA 
molecules and an Elongation Factor protein (termed EF-Tu in bacteria and eEF1A in eukaryotes) 
and how these interactions influence the delivery of aminoacylated tRNAs to the ribosome. We 
anticipate that our studies not only shed light on the basic mechanisms of molecular machines 
but may also help us to develop therapeutic or novel proteins that contain unnatural amino acids. 
Further, the manipulation of the translation machinery holds promise for the development of new 
methods to understand the origins of life. 
Along another line, we have used the power of synthetic biology to experimentally 
validate an evolutionary model. We exploited the functional diversity contained within the EF-
Tu/eEF1A gene family to experimentally validate the model of evolution termed „heterotachy‟. 
Heterotachy refers to a switch in a site‟s mutational rate class. For instance, a site in a protein 
sequence may be invariant across all bacterial homologs while that same site may be highly 
variable across eukaryotic homologs. Such patterns imply that the selective constraints acting on 
this site differs between bacteria and eukaryotes. Despite intense efforts and large interest in 
understanding these patterns, no studies have experimentally validated these concepts until now. 
In the present study, we analyzed EF-Tu/eEF1A gene family members between bacteria and 
eukaryotes to identify heterotachous patterns (also called Type-I functional divergence). We 
XV 
 
applied statistical tests to identify sites possibly responsible for biomolecular functional 
divergence between EF-Tu and eEF1A. We then synthesized protein variants in the laboratory to 
validate our computational predictions. The results demonstrate for the first time that the 
identification of heterotachous sites can be specifically implicated in functional divergence 
among homologous proteins. 
In total, this work supports an evolutionary synthetic biology paradigm that in one 
direction uses synthetic molecules to better understand the mechanisms and constraints 
governing biomolecular behavior while in another direction uses principles of molecular 

















1. ENGINEERING tRNA FOR THE EFFICIENT INCORPORATION OF                           
UNNATURAL AMINO ACIDS INTO THE PROTEIN TRANSLATION SYSTEM 
 
1.1. BACKGROUND AND SIGNIFICANCE 
Evolutionary Synthetic Biology 
Synthetic biology is a new area of biological research and has received considerable 
interest in the last decade. This field involves the synthesis of novel biological systems that are 
not usually found in nature. Synthetic biologists attempt to assemble unnatural components to 
generate novel systems with the goal of better understanding the principles of biology and 
evolution. The term synthetic biology was first associated with research into the engineering of 
control elements in existing genomes and the build up modified genomes by the Polish geneticist 
Waclaw Szybalski in 1974. In 1980, Barbara Hobom used the term to describe bacteria that had 
been genetically engineered using recombinant DNA technology (Hobom, B. 1980). In 2000, 
Eric Kool described the term as the synthesis of unnatural organic molecules that function in 
living systems (Rawls, R. 2000). Consequently, most of synthetic biologists are attempting to 
develop tools and methods to control interactions between DNA, RNA, and proteins because 
these interactions lie at the heart of living systems.  
Evolutionary synthetic biology aims to exploit evolutionary principles and models to 
develop engineered molecules and organisms. It also proposes to generate synthetic 
biomolecules to improve our understanding of evolutionary principles and structure/function 
relationships of biomolecules at the sequence level (Gaucher, E. Suddath Symposium, 2011). 
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 Overview Translation Mechanisms 
The majority of biological activities are carried out by proteins. The linear order of amino 
acids in each peptide directly (and sometimes indirectly) determines the structure and activity of 
a protein. Therefore, assembly of amino acids in their correct order is crucial to produce 
functional proteins in organisms.  Translation is a process that uses genetic information to create 
biological function. Translation takes place on the ribosome where mRNA functions as a 
template to join amino acids carried by an elongation factor protein (EF-Tu in bacteria and 
eEF1A in eukaryotes) and specific aminoacyl-tRNAs (aa-tRNA), to produce a polypeptide chain. 
The basic mechanism for translation is given in Figure 1.1.  Protein synthesis is generally 
divided into three fundamental phases, which are Initiation, Elongation, and Termination. During 
initiation of protein synthesis, the large and small ribosomal subunits assemble after mRNA 
associates with the small subunit of the ribosome. Amino acids are attached to their 
corresponding tRNAs by their cognate aminoacyl tRNA synthesis (aaRS). The resulting complex 
is called aa-tRNA. After activation of amino acid, the aa-tRNA complex is carried to the A site 
of the ribosome by EF-Tu. Correct codon and anticodon pairing results in the release of EF-Tu 
from the aa-tRNA complex. The target amino acid is transferred to the growing polypeptide 
chain. After each successive addition of amino acid, the de-acylated tRNA moves through the 
ribosome and is released at the E-site of the ribosome. This is known as the elongation phase. 
Translation keeps going in this manner until whole genetic information in mRNA is translated 
into protein. When the ribosome encounters a stop codon, protein synthesis enters the 
termination phase where the protein synthesis is ended by termination factors and ribosomal 





Figure 1.1. The general mechanisms of protein synthesis. Each amino acid is recognized by its 
specific aminoacyl-tRNA synthetase (aaRS) and charged with the appropriate tRNA to form an 
aminoacyl-tRNA comlex (aa-tRNA). aa-tRNA binds to the Bacterial Elongation Factor Tu (EF-
Tu:GTP) to form a ternary complex, which binds to the ribosome. Once the correct codon and 
anticodon pair occurs between mRNA and tRNA, GTP is hydrolyzed to GDP. This hydrolysis 
cause conformational change which results in the disassociation of EF-Tu from aa-tRNA and the 
aa-tRNA then moves to the E site of the ribosome. 
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In all steps, the required energy is provided by ATP or GTP hydrolysis. In general, the 
fidelity of protein synthesis in bacteria depends of the accuracy of codon-anticodon base-
pairing, correct charging of amino acid onto cognate tRNA, and EF-Tu‟s ability to 
discriminate between correctly charged and incorrectly charged tRNAs (Yaraus et al., 1995; 
Ibba et al., 1997; LaRiviere et al., 2001). 
 
 Engineering protein synthesis system 
In the past several years, there has been a great deal of interest in engineering RNA and 
proteins with the intentions that such engineered components may lead to both a better 
understanding of protein translation and help produce novel molecules that have therapeutic 
value. Despite this interest, manipulating the protein translation system is not straightforward. 
For instance, it is not easy to incorporate just any amino acid into the translation machinery 
because there are many checks-and-balances during protein synthesis, such as aminoacylation of 
tRNA, delivery of aa-tRNAs by EF-Tu, and incorporation of an amino acid (natural or unnatural) 
into a peptide chain by the ribosome. It is not exactly clear how the translation machinery 
achieves all of this specificity. Therefore, we have attempted to manipulate specific interactions 
in the protein translation machinery to better understand specificity. For instance, we are focused 
on the interactions between tRNA and EF-Tu with the intentions that we can manipulate these 
interactions to help us incorporate unnatural amino acids during protein synthesis. 
Transfer RNA (tRNA) 
The genetic code consists of 64 possible triplet codons which can be translated into a 
polypeptide composed of 20 possible amino acids. The polypeptides are coded by the triplet 
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codons on the mRNA (Crick, F. H., et al. 1961). The role of recognizing the triplet codons is 
given to the tRNA which is a relatively small RNA molecule, 72 to 95 nucleotides in length, and 
present in all three domains of life. There are about 46 different tRNAs present in E.coli and they 
are necessary for translating the genetic code (Sprinzl, Mathias. 2006). These tRNAs have two 
crucial functions: to recognize a specific codon on the mRNA and to accept the coded amino 
acid for transport to the A-site of the ribosome. tRNA identity underlies its capacity to be 
specifically catalyzed by aaRSs and thus to be responsible for the correct translation of  DNA 
into the protein (RajBhandary UL. 1994). The process of catalyzing an amino acid with its 
cognate tRNA is called aminoacylation (Figure 1.2.). Fundamentally, aminoacylation reaction is 
carrying out in two steps: 
Amino acid + ATP + Aminoacyl tRNA synthetase                  aaRS : aa - AMP                   (1) 
 
aaRS:aa-AMP +  tRNA                    aaRS + aa-tRNA + AMP                                                (2) 
 
In the first step, the amino acid is activated with ATP. In the second step, activated-amino 
acid is transferred to the 3‟ end of the tRNA by aaRS. 
The aminoacylation reaction must be quite specific for both their cognate tRNA and 
amino acid.  Although each aaRS is highly specific for its cognate amino acid, in some cases, it 
is hard to distinguish them due to high similarity between the functional groups for certain amino 






Figure 1.2. ATP-dependent aminoacylation of tRNA. An uncharged tRNA and appropriate 
(cognate) amino acid is aminoacylated by a specific aminoacyl-tRNA synthetase in the presence 
of ATP. ATP is hydrolyzed to AMP and once the amino acid is charged onto the tRNA, 
aminoacyl-tRNA synthetase disassociates from complex and aminoacyl-tRNA is now ready to 
participate in protein synthesis. 
 
During aminoacylation, each amino acid is accepted by its cognate aaRS. This part of 
translation is known as the specific phase because the aminoacylation reaction is very specific 
for both the tRNA and the amino acid (Dale and Uhlebeck, 2005). The traditional view of tRNAs 
was that they were interchangeable components and passive adaptors of protein synthesis 
(Woese, C.R. 2001).  However, Uhlenbeck et al. have demonstrated that each tRNA sequence 
has co-evolved with its cognate amino acid so tRNAs are active molecules and adapted to meet 
specific kinetic requirements of translation, so called thermodynamic compensation. Specifically, 
this means that the 20 cognate tRNAs:aa have similar thermodynamic contributions in their 
binding to EF-Tu. However, tRNA itself has a wide spectrum of thermodynamic contributions to 
EF-Tu binding. Uhlenbeck et al. essentially mischarged specific tRNAs with several different 
amino acids. They examined the interactions between those mischarged-tRNAs and their ability 
to bind EF-Tu (Schrader et al., 2009).  They determined whether EF-Tu recognizes a specific 
amino acid and binds tightly to it or recognizes a specific tRNA and binds tightly to it. This 
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relationship is inversely proportional (Figure 1.3). For example, if you have Glutamate – tRNA 
(Glu-tRNA) and that tRNA interacts strongly with EF-Tu, then the Glutamate itself will not 
interact strongly with EF-Tu. Conversely, if you have an amino acid that interacts strongly (e.g. 
glutamine) with EF-Tu, then the cognate tRNA will not interact strongly with EF-Tu. Thus, if 
you take a weak amino acid and aminoacylate it onto a weak tRNA then presumably that 
mischarged tRNA will not bind strongly enough to EF-Tu to be delivered to the ribosome.  
Therefore, if we want to make a protein or peptide that contains unnatural amino acids (ones that 
presumably are not able to strongly interact with EF-Tu) then we should attempt to bind such 
unnatural amino acids to a strong tRNA. In this situation, the complex should be delivered to the 
ribosome. So if we put this concept to work, we may convert a weak binding tRNA into a strong 
binding tRNA in terms of its interactions with EF-Tu and this presumably allows us then to 




Figure 1.3. Thermodynamic compensation of amino acids and tRNAs to EF-Tu. The order of 
thermodynamic contributions for most amino acids binding to EF-Tu has been determined 
experimentally and some of them have been predicted. The amino acid and tRNA hierarchies are 
approximately inversely proportional because the thermodynamic contributions of the amino 
acid and the tRNA balance one another. For example the Glu-tRNA is the strongest binder 
among the tRNAs, and the amino acid glutamate is the weakest binder to EF-Tu among the 
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Structure of tRNA 
Specialized tRNA functions in protein synthesis are mostly related to typical structural 
features. Given the important roles of tRNAs in living systems, it is desirable to manipulate 
tRNAs for understanding tRNA structure-function relationship and consequently generating 
proteins and organisms with new properties. This will enable us to provide novel tools for 
understanding biology in molecular terms and in studying various biological questions. A 
 
           
Figure 1.4. Structure of tRNAs. A) Cloverleaf folding highlights the different domains of the 
tRNA molecule. Length of tRNA molecule ranges from 72-95 nucleotides, with an average of 76 
nucleotides. Structural differences mainly originate from length variation in the D-arm and 
variable region. The CCA sequence at the 3‟ end is found in nearly all tRNAs. Attachment of an 
amino acid to the 3‟ A yields an aminoacyl-tRNA. B) Three-dimensional model of tRNA. L 




Two-dimentional tRNA structure is usually described in cloverleaf-model. All tRNAs 
contain the residues CCA at the 3′ terminus. The cloverleaf-modeled tRNA structure has four 
arms: (a) The acceptor stem (A) accepts the amino acid at the CCA-3′ sequence and binds to the 
EF-Tu molecule; (b) The TψC (T) loop is so named because of the presence of this triplet 
sequence. This loop also binds to the EF-Tu molecule; (c) The anticodon loop located at the 
opposite end of the acceptor arm. This arm carries the anticodon triplet in the center of the loop 
and is responsible for codon-anticodon base pairing. (d) The D loop is so named because it is 
rich in dihydrouridine, a modified base.  There is one extra arm located between the TψC and 
anticodon arm of variable length. The significant function of this arm has not been determined 
yet for most tRNAs. One of the structural distinctive futures of tRNA is that they contain 
nonstandard bases and pairings. The most significant such pairing is the G:U non Watson-Crick 
base-pair. 
 
 G:U Non-Watson Crick Base Pair 
The G:U wobble base pair is a non-Watson-Crick base pairing, which is essential for 
RNA structure. G and U bases interact via two hydrogen bonds in the same manner that Watson-
Crick base pairing occurs (Ladner et al., 1975). Subsequent studies have shows that the G:U pair 
provides unique recognition sites and can have a major impact on how ancillary binding 
interactions occur (Gabriel et al., 1996; Varani et al., 2000; Agris et al., 2007). Studies have also 
showed that tRNA binds to EF-Tu via its Acceptor and T stems where G:U wobble base pairs 
may be responsible for either weak- or strong-binding of this complex. Again, we have learned 
from previous studies that the G:U wobble base-pair presents an electronegative environment in 
the tRNA structure where EF-Tu binds (Figure 1.5).  Xu and his coworkers have found that the 
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GU pair increases negativity when compared with standard G:C or A:U base pairs in the major 
groove of RNA. Conversely, when in the minor groove, G:U decreases negativity. We have 
hypothesized that positive amino acids in EF-Tu should bind tightly to the G:U wobble base pair 
while negative amino acids bind weakly to the tRNA‟s region when interacting with G:U pairs. 
Our bioinformatic analyses have discovered that so-called strong binding tRNAs have a G:U 
pairing in particular regions of the tRNA structure while the so-called weak binding tRNAs have 
G:U in different regions of the tRNA structure. Typically, a G:U around the acceptor stem seems 
to be correlated to the strong binding tRNAs while the weak binding tRNAs mostly have G:U 
base-pairs around the T stem (Table 1.1). 
 
Figure 1.5. G:U wobble base pair. A) Surface electrostatic potential maps of Watson-Crick G:C 
and G:U wobble base pair. Red color represents negative potential and blue represents positive 
potential regions. B) Representative scheme between Guanine and Uracil, their interaction via 
two hydrogen bonds.  Varani et al., (2000). 
 
Despite substantial interest and a few studies, no study has ever established a rule based 
on the distribution of the G:U wobble base-pair in tRNA structures. Therefore, we have 
attempted to determine sequence structure-function relationships of tRNAs and their interactions 
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with EF-Tu, regarding the G:U wobble pairing. To test our idea, we have elected to use Valine 
(Val)-tRNA as a model.  
 
Table 1.1 Relationships between different tRNA species for EFTu with the presence of G:U base 
pairs in the Acceptor or T stem and their recruitment into the genetic code. All tRNA species 
come from E. coli K-12 strain.  
tRNA Anticodon G:U  base pair Affinity for EFTu 
Aspartate GUC 49:65 strong 
4:69 
Glycine GCC 49:65 strong 
CCC 
Threonine CGU 49:65 strong 
Alanine GGC 3:70 strong 
UGC 
Phenylalanine GAA 51:63 weak 
Valine UAC 50:64 weak 
GAC 49:65 studied here 
f-Methionine CAU 50:64 weak 
Tryptophan CCA 50:64 weak 
Histidine GUG 49:65 unknown 




 Engineering Valine-tRNA 
We engineered Val-tRNA by introducing site specific mutations based on our 
bioinformatic analysis. For the present study, we used Val-tRNA because it shows moderate 
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binding to EF-Tu, which enable us to convert this tRNA into either a strong- or weak-binding 
tRNA. As a first step, we wanted to introduce individual mutations to the specific regions of the 
tRNA that interact with EF-Tu. Therefore, we introduced mutations to the acceptor and T stem 
of tRNA in order to create G:U wobble pairs. Nevertheless, to see the affect of G:U pairings at 
specific sites, we also introduced a mutation to eliminate the G:U pair located in wild type Val-
tRNA at 50:64 position. To investigate our idea, we charged Val-tRNA with Glutamate (Glu) 
which is a weak amino acid and Glutamine (Gln) which is known a strong amino acid. We 
hypothesized that the Val-tRNA
Gln
 pair would participate in translation more efficiently than 
Val-tRNA
Glu


















1.2. MATERIALS AND METHODS 
Materials 
Bacterial Strains: Escherichia coli strain and genotypes 
For general cloning and screening, we used One Shot TOP10 Chemically Competent E. 
coli cells (Invitrogen) which provides a one-step cloning strategy for the direct insertion of Taq 
polymerase-amplified PCR products into a plasmid vector. 
The genotype of TOP10 F
-
 mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacΧ74 
recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG 
 
Vector 
We used pCR2.1-TOPO vector ((Invitrogen) for chemical transformation of PCR 
product. Antibiotic resistance: carbenicillin and kanamycin. For details see appendix. 
 
 Oligonucleotides 
Synthetic PCR primers were purchased from Integrated DNA Technologies (IDT) Inc. 
All primers used in this study are shown in Table 1.2. The primers were diluted up to 100 uM 
and stored at -20 °C. 
 
Table 1.2: The primers used throughout this study. DNA sequences are also provided for each 
variant. Synthesized primers were used to construct template DNA and amplifying primers were 
used to amplifying the template. 
Wild Type   DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GGC GGT TCG ATC CCG TCA TCA CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GGC GGT T- 3' 
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Synthesize wt tRNA rev: 5'-TGG TGG GTG ATG ACG GGA TCG AAC CGC CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer: 5'- TGG TGG GTG ATG AC- 3' 
64 T C DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GGC GGT TCG ATC CCG CCA TCA CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GGC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG GTG ATG GCG GGA TCG AAC CGC CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer: 5'- TGG TGG GTG ATG GC- 3' 
50 G A DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TCA TCA CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG GTG ATG ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer: 5'- TGG TGG GTG ATG AC- 3' 
50 G A  
65 C T 
 
DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TTA TCA CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG GTG ATA ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer: 5'- TGG TGG GTG ATA AC- 3' 
50 G A 
51 C T 
 DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAT GGT TCG ATC CCG TCA TCA CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAT GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG GTG ATG ACG GGA TCG AAC CAT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer:  5'- TGG TGG GTG ATG AC- 3' 
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50 G A 
72 C T 
DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TCA TCA CCT ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TAG GTG ATG ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer: 5'- TGG TAG GTG ATG AC- 3' 
50 G A 
71 C T 
DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TCA TCA CTC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGA GTG ATG ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer:  5'- TGG TGA GTG ATG AC- 3' 
50 G A 
70 C T 
DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TCA TCA TCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG ATG ATG ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer:  5'- TGG TGG ATG ATG AC- 3' 
50 G A 
69 A T 
DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GAC GGT TCG ATC CCG TCA TCT CCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GAC GGT T- 3' 
Synthesize wt tRNA rev: 5'-TGG TGG GAG ATG ACG GGA TCG AAC CGT CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 
Amplifying reverse Primer:  5'- TGG TGG GAG ATG AC- 3' 
70 C T  DNA sequence: 5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC AAG GAG 
GGG GTC GGC GGT TCG ATC CCG TCA TCA TCC ACC A- 3' 
Synthesize wt tRNA fwd:  5'-GGG TGA TTA GCT CAG CTG GGA GAG CAC CTC CCT TAC 
AAG GAG GGG GTC GGC GGT T- 3' 
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Synthesize wt tRNA rev: 5'-TGG TGG ATG ATG ACG GGA TCG AAC CGC CGA CCC CCT 
CC- 3' 
Amplifying forward Primer: 5'-TAA TAC GAC TCA CTA TAG GGT GAT TAG CTC AGC- 3' 









Molecular biology techniques 
 
Standard molecular biology protocols were used for DNA electrophoresis, restriction 
digestion, ligation, and bacterial transformation. Enzymes were purchased from New England 
Biolabs and Promega. 
 
Primer design and template construction 
 
For each variant we have two primers to construct the template and two primers to 
amplify template DNA. All primers were purchased from IDT. To synthesize the wild-type and 
variant genes, three PCR steps were applied; gradient, template construction-amplification, 
template amplification after sequence verification. Gradient PCR was performed to find optimum 
annealing temperatures for the variants.  Template primers were mixed with 5X GoTaq buffer, 
dNTPs, GoTaq polymerase and water was added up to a 25 μL reaction volume. PCR was run, 
but after 4 cycles, amplifying primers were then added. The PCR conditions are summarized in 





Table 1.3: PCR reaction. The following PCR reaction set up for 25 μL.  
Component Final Concentration Volume/25μL rxn 
Water ___ 14.25 μL 
5X Go Taq colorless Buffer 5X 5 μL 
dNTPs 10mM 0.5 μL 
T7 Amplify-tRNA fwd primer 10 μM 2 μL 
Amplify-tRNA rev primer 10 μM 2 μL 
Synthesize tRNA fwd primer 1 μM 1 μL 
Synthesize tRNA rev primer 1 μM 1 μL 
Go Taq polymerase 5U/μL 0.25 μL 
 
 
Table 1.4: PCR cycling parameters. The annealing temperature varies depending on the variant‟s 
primers and template. 
Step  Time Temperature Cycles 
Initial Denaturation 3 min 95 °C 1X 
Denaturation 30 sec 95 °C  
34X Annealing 30 sec 52 °C 
Extension 30 sec 72 °C 




QIAgen Gel Extraction protocol 
Fragments of DNA generated by the PCR reaction were separated using standard DNA 
electrophoresis (0.8% agarose gel). DNA bands corresponding to the desired products were 
identified using a UV transilluminator and bands were excised from Ethidum Bromide (EtBr) 
stained gels by using a scalpel. Separation of DNA from gel was achieved by using the QIAgen 
Gel Extraction Kit and protocols supplied by the manufacturer (QIAgen). Basically, the gel slice 
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was weighted in a 1.5 mL microcentrifuge tube and mixed with 3 volumes of QG buffer 
containing guanidine thiocyanate. Samples were incubated at 48 °C until the gel slice has 
completely dissolved and the optimal pH for DNA binding to the spin column was adjusted by 
using 3 M sodium acetate (pH 5.0). To increase the yield of DNA fragments, 1 gel volume of 
isopropanol was added to the sample and mixed. The sample was loaded into the column, 
provided by manufacturer, and centrifuged. The column was washed with PE buffer containing 
ethanol and the DNA was eluted with 50 μL sterile molecular grade water (pH 7.5) (Mediatech 
Inc).   To increase DNA concentration, the tube was incubated for 3-5 min at room temperature 
before centrifugation. The purified DNA was stored at –20 °C. 
Cloning Procedures 
One Shot TOP10 Chemically Competent E. coli cells were used for cloning. Although a 
detailed-procedure can be obtained from manufacturer (Invitrogen), the basic protocol is as 
follows: cleaned-up PCR product was mixed with TOPO vector and  salt solution. We added salt 
(200 mM NaCl; 10 mM MgCl2) to increase transformation efficiency up to 3 fold. The mixture 
was incubated at room temperature for several minutes (min), and then the reaction was 
transformed to E. coli competent cells and incubated on ice for several min. After incubation, the 
cells were heat-shocked for 45 seconds at 42 °C and immediately transferred to ice. The sample 
was shaken at 37 °C for 1 hr in S.O.C. medium, and then plated on carbenicillin  and kanamycin 
selective plates.  
Next day, 5 single white colonies were taken from the selective plate and inoculated 
individually in 4 mL LB (Luria-Bertani) medium containing 100 μg/mL carbenicillin and 






Table 1.5: Set up TOPO cloning reaction for eventual transformation into chemically competent 
TOP10 One Shot E. coli. 
Reagent Chemically Competent E. coli 
Fresh PCR product  0.5 to 4 μL 
Salt Solution 1 μL 
TOPO® vector  1 μL 
Water  add to a total volume of 5 μL 






Plasmid DNA Purification 
 
The plasmid DNA was isolated using QIAprep Spin Miniprep Kit from QIAgen. The 
bacterial cells were transfer into a microcentrifuge tube and collected by centrifugation
*
 at room 
temperature. The pellet resuspended in buffer P1 (lysis buffer and RNase-A), buffer P2 (contains 
sodium hydroxide), and buffer N3 (contains guanidine hydrochloride, acetic acid), respectively. 
After cells lysate was clarified by centrifugation, the supernatant was load on the QIAprep spin 
column and washed with Buffer PE. The plasmid DNA elution was achieved in a 1.5 mL sterile 
microcentifuge tube by 50 μL sterile molecular grade water (PH 7.5), Mediatech, Inc. The 





All centrifugation steps were carried out at 13,000 rpm (~17,900 x g) in a conventional, table-





To confirm that the DNA plasmids were cloned in the correct orientation, the samples 
were sequenced by Genewiz Inc. The samples were diluted to 50 ng/µL by using sterile water.  
For each reaction, 8 µL of the DNA plasmid at 50 ng/µL provided in a labeled 0.2 mL PCR tube 
and cap. After verifying the sequences the DNA was amplified via PCR.  The 25 μL PCR 
reaction set up according to table 1.3 and 1.4. 
 
Cleanup Amplified PCR Reaction: MinElute 
 
Amplified DNA was cleaned using MinElute PCR Purification Kit (QIAgen) because this 
kit isolates only the DNA fragments between 70-4000 nucleotides. 5 volumes of Buffer PB were 
added to 1 volume of the PCR reaction and mixed. pH was optimized by 3 M sodium acetate (pH 
5.0). The samples were applied to the column and washed and then eluted with 10 μL sterile 
water. Detail information can be found from the manufacturer.  
 
In Vitro Transcription 
The MEGA shortscript high yield transcription kit from Ambion was used for in vitro 
transcription. Although the incubation time varies for a specific reaction, the general 
transcription protocol is summarized in Table 1.6. 
The moles of template DNA were calculated from the mass, by using the equation below. 
The average molecular weight of all four nucleotides (330 g/mol) can be used instead of the 





Table 1.6: Assembly of in vitro transcription reaction. Following components were mixed at 
room temperature and incubated in a water-bath at 37 °C. 
Amount  Component 
2 μL  T7 ATP Solution (75 mM) 
2 μL  T7 GTP Solution (75 mM) 
2 μL T7 CTP Solution (75 mM) 
2 μL T7 UTP Solution (75 mM) 
2 μL T7 10X Reaction Buffer 
2 μL T7 Enzyme Mix 
<8 μL Template DNA 
Water (Nuclease-free) to 20 μL final volume. 
~ 4-6 hr incubation at 37 °C. After incubation add 1 μL of 
DNase and incubate at 37 °C for additional 15 min. 
 
MW of template = Ave MW per bases x # of base (x 2 for double-stranded) 
Moles of template = Mass of template / MW of template 
Because each of our variants has 76 bp, the moles in 1 μg of a 76 bp PCR product (double 
stranded):  
MW of template = 330 g/mol x 76 x 2 = 5.016x10
4
 g/mol                                     
Moles of template = (1 μg)/ (5.016x 10
4
 g/mol) = 20 pmol of template 
The reaction was assembled in an RNase-free microfuge tube (Eppendorf) at room 
temperature. The contents were mixed thoroughly by gently flicking the tube, and then the 
mixture was incubated at 37 °C. For most applications, a 4 hr incubation was sufficient, but for 
some reactions the incubation time was extended up to 6 hr. After sufficient incubation, the DNA 
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template was removed by adding 1 μL of TURBO DNase to the reaction and continued the 
incubation at 37 °C for an addition 15 min.  
The reaction was terminated by adding 1/2 volume of Gel Loading Buffer II (Ambion).  
The sample was incubated at 80 °C for 3 min and additional 3 min at room temperature. The 
products were loaded on a 4-15% Tris-HCI denaturing polyacrylamide gel and the reaction was 




Figure 1.6: Polyacrylamide Gel Electrophoresis (PAGE) of RNA. tRNAs were loaded on a 4-
15% Tris-HCI denaturing polyacrylamide gel and the reaction was run at 150 volt for 45 min. 
The gel was visualized by short wave U.V. 
 
After electrophoresis, the gel was covered with polyvinyl chloride to prevent any 
contamination. The area of the gel that contains the full-length transcript was visualized using a 
short wave UV lamp and the area containing the nucleic acid was marked with a pen. The 
marked-area was cut out with a sterile razor blade and transferred into an RNase-free microfuge 
tube containing 400 uL of sterile RNA-free water. The tube was incubated at 4 °C for overnight 
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with shaking at 10 rpm. Next day, the liquid part was transferred in a new tube and added 6/100 
volume of 5 M NaCl and 2.5 volumes ethanol. After vortexing, the tube was incubated at –20 °C 
for at least 6 hr. The sample was centrifuged at 4 °C for 45 min at a 21000 x g to pellet the RNA. 
The supernatant solution was removed carefully and the pellet resuspended in 25 uL of sterile 
RNA-free water and kept on ice. The tRNA was assessed by UV absorbance using Nanodrop 

































1.3. RESULTS AND DISCUSSIONS 
 
In vitro techniques were used to investigate sequence structure-function relationships of 
tRNAs and their interactions with EF-Tu. Binding affinity of EF-Tu to the G:U wobble base 
distribution on tRNA structure is indirectly inferred based on the ability to participate in protein 
translation. The T and Acceptor stems of tRNA sequences were selected to mutate at sites 
predicted to be responsible for weak binding or strong binding.  
We introduced G:U mutations to different regions of the tRNA and demonstrated the 
importance of G:U wobble base-pairs in tRNA participation in translation. We anticipate that our 
study can be further applied to biomedicine since many new therapeutics require the 
incorporation of unnatural amino acids into peptides or proteins.  In the current study, we used 
Protein synthesis Using Recombinant Elements (PURE) in vitro translation system to 
demonstrate participation of mutant tRNAs during peptide translation. To identify efficiency of 
tRNAs in translation, we charged wild type and all mutant tRNAs with Glutamate (a week amino 
acid) or Glutamine (a strong amino acid). 
 
Determine G:U mutations in Valine-tRNA 
The G:U pair is a fundamental unit of nearly all tRNAs. We introduced individual 
mutations to specific regions of the tRNAs that interact with EF-Tu. Therefore, we introduced 
mutations to the acceptor and T stem of tRNA and created G:U wobble base-pairs not naturally 
present in the Val-tRNA species. Those mutations are highlighted in red in figure 1.7. In 
addition, to determine the effect of G:U pairing at specific sites, we also introduced a mutation to 







Figure 1.7: Engineered Val-tRNA variants. G:U mutations (highlighted in red) were introduced 








Cloning and Amplification of DNA 
 
PCR primers were designated as template and amplifying primers. T7 promoter was 
introduced in order to transcribe DNA into RNA. Designated primers were synthesized by IDT. 
Although PCR conditions are described in materials and methods, first template primers were 
amplified for four cycles and then amplifying primers were added to amplify template DNA for 
an additional 30 cycles. The optimal amplication conditions were determined by gradient PCR 
and template was amplified using standard PCR conditions which are also described in material 
and methods section. Optimal annealing temperature displayed diversity, but highest products 
were mostly captured in 50-52 °C temperature range. The PCR products were cleaned up using a 
QIAgen gel extraction kit. The length of our DNA was the standard E. coli Val-tRNA length 




Figure 1.8: Gradient PCR.  On the left side marker is shown and the PCR product corresponding 
to 93bp. The annealing temperature gradient was from lanes 1 to 8 was 60°C, 59.4°C, 58.3°C, 
56.3°C, 53.9°C, 52°C, 50.7°C, 50°C, respectively. The higher products were captured at 50-52°C 






Purified-PCR product was successfully ligated into the TOPO vector using TOPO TA 
Cloning Kits (Invitrogen). This kit provided efficient cloning for our direct insertion of amplified 
PCR products into the plasmid vector. Basically, single T overhangs for TA cloning is possible 
because the plasmid vector is already linerized. Then Topoisomerase I covalently binds to the 
vector and Taq polymerase-added single A to the 3´ ends of PCR products. This allowed PCR 




Figure 1.9: Insertion of PCR product into Topo Vector. Topoisomerase-I binds to duplex DNA 
and cleaves the phosphodiester backbone after 5′-CCCTT in one strand. The phospho-tyrosyl 
bond between the DNA and enzyme can be attacked by the 5′ hydroxyl of the original cleaved 




To analyze constructs, plasmid DNA was purified and DNA sequences were verified by 
sequencing (Genewiz Inc) by using the M13 Forward (-20) and M13 Reverse primers. Verified 
plasmid DNA was used as a template DNA and amplified by PCR (Figure 1.10).  The PCR 
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conditions were similar to conditions that were summarized in materials and methods in table 1.3 






Figure 1.10: Amplified DNA-tRNA. DNA was load on 0.8% Agarose-EtBr gel and visualized 
by UV. 3000bp correspond template plasmid and the amplified DNA is 93bp. 
 
 
In Vitro transcription 
 
Wild-type and variants were successfully transcribed into tRNAs. In vitro transcription 
reaction is described in materials and methods.  PCR product that contains a T7 RNA 
polymerase promoter was used as template for in vitro transcription. The template DNA was 
prepared free of contaminating proteins, nonspecific DNA, and RNA. The components were 
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assembled at room temperature and incubated at 37 °C for 4-6 hr. In order to get pure RNA 
product, template DNA was removed by DNase. The transcription reaction was purified by using 
4-15% Tris-HCI polyacrylamide gel. To prevent any contamination, each time one 
polyacrylamide gel was used only for one variant of Val-tRNA. The amount of template and 
incubation time played a major role on transcription efficiency. Low amount of template DNA 
caused low yield or no product, using higher amount of template caused having unspecific 
products (Figure 1.11).  
 
 
       
 
 
Figure 1.11: In vitro transcription: wild-type Val-tRNA by using different amount of template 
DNA 50 nM, 100 nM, and 200 nM respectively. The Marker (2 ul of Century Size Markers, 
Ambion) and samples were mixed with 10 uL of Gel Loading Buffer II.  The samples were 
incubated at 80 °C for 3 min and 3 additional min at room temperature. The products were 
loaded on a 4-15% Tris-HCI denaturing polyacrylamide gel and the reaction was run at 150 volt 
(1X TBE Buffer). After electrophoresis, the gel was incubated in 100 mL water that contained 
100 uL diluted EtBr for 5 min and visualized by UV.  
 
After standard mini electrophoresis, the transcription product was visualized by short 
wave UV and cut out with a sterile razor blade and transferred into sterile RNase-free water. 
Overnight incubation in water allowed the tRNAs to migrate from the gel slices into the water. 
The RNA was recovered by precipitation using 100% ethanol and eluted with RNase-free water. 
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In some cases, low product of tRNA made it difficult to see the pellet, so the supernatant was 
carefully removed immediately after centrifugation. The tRNA was quantified by using 
Nanodrop ND-1000A UV-Vis Spectrophotometer (Figure 1.12). Transcription yields varied 
depending on the variant and the template quality. For low yield reactions, the number of 




Figure 1.12: Quantification of in vitro transcription product. The tRNA was assessed by UV 
absorbance using Nanodrop ND-1000A UV-Vis Spectrophotometer. 
 
 
In Vitro Translation (PURE system) 
Affinity of mutant tRNAs to EF-Tu were indirectly assessed by quantification of peptide 
produced using the PURE system. Except for the ribosomes and tRNAs, the PURE system 
contains all of the E. coli components necessary for protein translation (Shimizu, Y., et al., 
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2001). In vitro translation assay was performed with our collaborator Dr. Matthew Hartman and 
his laboratory at Virginia Commonwealth University.  
 
 
Assay with Glutamate (Glutamic Acid) 
All tRNAs were charged with glutamate which has been identified as a weak amino acid.  
To identify efficiency of mutant tRNAs in translation, we assayed the incorporation of each 
mutant tRNA at a single site in a short peptide containing an N-terminal His-tag. We have used a 
template MHHHHHHMVHM, where V is the codon that we were interested in covering with 
one of the mutant tRNAs or wild-type. Wild type Val-tRNA was used as control and the yield of 
reaction (amount of produced peptide) was determined as 100% and all other results are relative 
to the wild-type. We tested the entire mutant tRNAs and compared them with wild-type in vitro 
transcribed Val-tRNA.  Figure 1.13 shows results for Val-tRNAs
Glu 
variants. Because glutamate 
itself is a weak amino acid and Val-tRNA shows moderate or weak affinity to EF-Tu, we did not 
anticipate a high yield of peptide in comparison to a strong binding amino acid on the weak 
tRNA. Our result with wild-type Val-tRNA performed as predicted. If we look at the secondary 
structure of wild-type Val-tRNA, we notice that there is only one G:U base-pair (position 50-64) 
in the T stem at a position where we predict that  G:U would decrease binding affinity of tRNA 
to EF-Tu. To verify our prediction that a G:U pair at the 50-64 position would decrease the 
interaction with EF-Tu, we introduced mutations to those sites to remove the G:U pair. Results 
were parallel with our prediction in which removal of the G:U at those sites would increase the 
amount of peptide produced. We then moved to position 49-65 on the T stem of the tRNA. We 
changed C to U at 65 position resulting in a G:U at 49:65. Note, due to the G:U at 50:64, we also 
mutated pair 50:64 to get rid of the G:U in this variant [The same applies for many of the 
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variants we produced]. Translation yields nearly doubled for this variant and interestingly this 
was the highest yield among the entire mutant tRNAs that were mis-acylated with Glutamate. 
We also introduced a G:U mutation to the 51:63 pair and this resulted in a low amount of peptide 
produced. Overall, results in the T stem of tRNA showed that G:U lead to a decrease in 
participation of tRNA during translation at positions 50:64 and 51:63. Conversely, G:U in 
position 49:65 increased the participation of tRNA during translation.  Previous studies support 





Figure 1.13: Peptide synthesis assay with Val-tRNA variants charged with glutamate. Average 
yields for successful translations producing peptides. We used an mRNA template corresponding 
to a MHHHHHHMVHM peptide where V served as our site of interest for incorporation of our 
mutant tRNAs. We tested wild type and all of the mutant Val-tRNAs, by charging with 
glutamate using a Flexizyme and the in vitro PURE translation system.  We measured the yield 
of the peptides produced. Wild type Valine tRNA was used as control and the yield of reaction 
(amount of produced peptide) was used as a reference of 100% and all other results relative to 





























Mutant  G:C            A:U AU+GU       AU+UG       AU+GU      AU+GU      AU+GU     AU+UU          G:U




In addition to the T stem of tRNA, we also introduced G:U mutations to the A stem of 
tRNA because EF-Tu binds to the A and T stems of tRNA. We introduced mutations at position 
pairs 1:72, 2:71, and 3:70. In all these three cases, a G:U pairing increased peptide production 
nearly 1.5 fold in comparison to the wild type. As mentioned above; beside these mutations, we 
kept the mutation at position 50 which removed the G:U in order to understand the context-
dependent affects of these mutations. 
 
 
Assay with Glutamine 
 
To further dissect the system, we performed the same assay but with glutamine, which is 
known as a strong-binding amino acid in terms of its interactions with EF-Tu. Therefore, we 
predicted more tRNA participation in translation in comparison of glutamate. Again, wild type 
and mutant tRNAs were aminoacylated with glutamine and the same mRNA template was used.  
As we performed in the assay with glutamate, wild type Val-tRNA was used as control and the 
amount of produced-peptide was referenced as 100% and all other results are presented relative 
to the wild type glutamate. We analyzed all of the mutant tRNAs and compared them with the 
wild-type in vitro transcribed Val-tRNA.  Figure 1.14 shows the results for Val-tRNA
Gln 
 
variants.  The assay with glutamine resulted in similar patterns as the assays conducted with 
glutamate – the only exception being the higher yields due to the fact that glutamine is a strong-
binding amino acid. Again, a G:U pairing at position 50:64 and 51:63 appeared to decrease 
affinity of  Val-tRNA
Gln 
to EF-Tu as measured by peptide produced. Conversely, G:U pairings at 
position 49:65 on the T stem and positions 1:72, 2:71, 3:73 on the accepter stem increased the 
ability of the mutant Val-tRNA
Gln 






Figure 1.14: Peptide synthesis assay with wild-type and mutant Val-tRNAs charged with 
glutamine. Average yields for successful translations producing peptides. We used an mRNA 
template corresponding to a MHHHHHHMVHM peptide where V served as our site of interest 
for incorporation of our mutant tRNAs. We tested wild type and all of the mutant Val-tRNAs, by 
charging with glutamine using a Flexizyme and the in vitro PURE translation system.  We 
measured the yield of the peptides produced. Wild type Valine tRNA was used as control and the 
yield of reaction (amount of produced peptide) was used as a reference of 100% and all other 











































Mutant    G:C            A:U AU+GU     AU+UG       AU+GU       AU+GU      AU+GU     AU+UU         G:U







Based on overall results, we have demonstrated that the G:U wobble pair plays an 
important role in participation of aminocylated-tRNA in the translation system.  We have 
mapped a G:U distribution onto the tRNA structure based on our analysis (Figure 1.15).  For the 
most part, a G:U wobble base-pair in the acceptor stem increases participation of aminoacylated-
tRNA in protein synthesis; whereas, a G:U pair in the T stem decreases participation with the 
exception at position 49:65 which enhances participation.   
Although our results are mostly consistent with Uhlenbeck‟s thermodynamic 
compensation model, there are some minor variations. These variations might be due to the fact 
that we studied a different species of tRNA.  In previous studies, Uhlenbecks and colleagues did 
not specify which Val-tRNA species they used thus making a direct comparison difficult. We 
will need to conduct further investigations with different tRNA species in order to establish a 
hypothesis based on effects of the G:U wobble base-pair in tRNA participation during 
translation.  
We are confident that our results can next be exploited to generate tRNA species charged 
with unnatural amino acids with the intention that the engineered species will enhance 
incorporation of the unnatural amino acid during peptide synthesis. Such experiments are 








Figure 1.15: G:U base pair distribution on tRNA based on participation in peptide translation. 
The representative tRNA is the wild-type Val-tRNA. The regions that appear to increase 
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2. FUNCTIONAL DIVERGENCE AMONG HOMOLOGOUS PROTEINS 
2.1. BACKGROUND AND SIGNIFICANCE 
 Functional Divergence 
Members of functionally-diverse homologous protein families can be used to study 
structural determinants of protein function and the relationship between evolving protein 
structure and function. Functional diversification within a protein family should most often 
correspond to changes in protein sequence. Functionally important amino acid residues are 
conserved throughout evolutionary history. Alternatively, a change in amino acid conservation at 
a specific site may be a sign of functional divergence. Most research groups in the molecular 
evolution community focus their efforts on sites in a sequence and attempt to understand how 
historical mutations drive functional diversification. This focus is a consequence of the truism 
that the selective constraint acting at a site is inversely related to evolutionary rate of change at 
that site (Gaucher et al., 2002). Following this idea, statistical models have been developed by 
many groups to understand and test functional divergence within a protein family (Gu, 2003-
2006; Wang et al., 2006; Knudsen et al., 2001).  
Rate Heterogeneity and Heterotachy 
Rate heterogeneity is a well-established pattern used by evolutionary biologists to dissect 
a collection of sequences. Rate heterogeneity is defined as unequal mutation rates among 
sequence positions within a collection of aligned sequences. The substitution rate of sites in a 
given gene family can change through their evolutionary history. Therefore, this variability in 
evolutionary rate can have an impact on analyses such as those that infer phylogenetic tree 
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generation, which is important for the study of evolution (Revell et al., 2008). Rate heterogeneity 
across sites is captured by a so-called gamma distribution and its shape parameters, α; basically, 
an increase in α corresponds to a decrease in the rate variation across sites (Goldman and 
Whelan, 2000). For example, a set of four homologous genes of four amino acids positions from 
four different species is shown in figure 2.1.  If we assume that each square represents one unit 
of evolutionary change, the site-specific substitution rate will be different due to unequal 
mutation rates among the sequence positions. For instance, in the representative scheme, the first 
two positions represent a low evolutionary rate and they are constant throughout the history of 
the four species. In the third position, the mutation rate is moderate. The forth position, however, 
represents a rapidly evolving site and may be indicative of altered selective constraints acting at 
this position. 
 
Figure 2.1. A hypothetical scheme showing rate heterogeneity of sites within homologous genes 
from four species. Left, hypothetical amino acid alignment for the given gene. The first two 
amino acid positions are identical but the last two are variable. Right, each square represents one 
unit of evolutionary change, the first two positions represents low evolutionary rates. The third 
position represents a moderate amount of mutation, or evolutionary change. The forth position 
represents a rapidly evolving site. 
Previous studies have shown that variable rates at specific sites can cause changes in the 
structure and function of a protein (Miyamoto and Fitch 1995; Philippe and Lopez 2001). The 
traditional view of protein sequence change was that the replacement rate at individual sites stays 
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constant throughout evolutionary history, which is called homotachous model. This model 
presumes that conserved sites are always evolving slowly, and that non-conserved sites are 
rapidly evolving across the entire phylogenetic tree (Yang 1996a). 
 For example, as shown in the figure 2.2., the first and third sites are evolving slowly, the 
second site is moderately evolving, and the fourth is rapidly evolving. Under the homotachous 
model, we typically assume that this process remains constant throughout evolutionary history. 
Therefore, the last common ancestor of life evolved into bacteria and eukaryotes and the 
mutation rate stayed the same throughout time, so the first site remained slow-evolving in both 
bacteria and eukaryotes and the last site remained fast-evolving in bacteria and eukaryotes as 
well. 
 
            
Figure 2.2. Homotachous (A) and heterotachous (B) rate heterogeneity models. The last 
common ancestor of life diverged to give rise to bacteria and eukaryotes. Homotachy can be 
considered a form of purifying selection whereas Heterotachy can be considered a form of 
diversifying selection. 
 
However, later studies have shown that a homotachous model is insufficient to capture 
the site specific rate shift for protein-coding sequences (Fitch and Markowitz, 1970; Miyamoto 
and Fitch, 1995; Gaucher et al., 2001). These studies implied that selection at the organismal 
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level can be variable at particular sites of DNA and protein. Specifically, this means that 
positions have variable rates of mutations in different branches of an evolutionary tree (Gaucher 
et al., 2001). Again, in the representative figure, we have the same common ancestor and 
distribution of site-specific rates (two slow, one moderate, and one rapid). However, this time, 
after the split that gives rise to bacteria and eukaryotes, the first site changes from slowly 
evolving to now rapidly evolving, and the fourth site goes from rapidly evolving to now slowly 
evolving. Thus, these shifts in rate may have arisen in response to a shift of functional constraints 
operating on this gene as it diverges between bacteria and eukaryotes and may lead to minor 
modifications in its functionality or properties between these two domains of life.  
Evolutionary biologists have developed site-specific rate shift models under both the 
heterotachous and homotachous model framework to determine which model is the most suitable 
for a given dataset (Philippe, H. et al. (2000); Gaucher et al. (2002); Cole et al. (2010); 
Kolaczkowski et al. (2008)). Gaucher et al. have compared Elongation Factor (EF) gene families 
of bacteria and eukaryotes under the non-homogeneous rate heterogeneity model (Figure 2.3). 
They analyzed EF sequences using the DIVERGE software (Gu et al., 2002) to identify 
evolutionary rates of sites which have undergone site-specific rate shifts. They have identified 
some sites that rapidly evolve in bacteria but slowly evolve in eukaryotes and vice verse. They 
showed the distribution of sites associated with a shift in evolutionary rates between bacteria and 
eukaryotes. For example in the figure 2.3., green shows the sites that are rapidly evolving in 
bacteria but slowly evolving in eukaryotes. Conversely, the sites highlighted in red are rapidly 
evolving in eukaryotes but slowly evolving in bacteria. The goal then is to make functional 








Figure 2.3. Distribution of heterotachous sites onto the three dimensional structure of EF-Tu (a) 
and eEF1A (b). Nucleotide exchange factors (EF-Ts and eEF1B) are represented in circle. Green 
identifies sites that are evolving more slowly in eukaryotes relative to bacteria, and red sites are 
rapidly evolving in eukaryotes than in bacteria. Different domains of the proteins are numbered 
1-3 (Gaucher et al. (2002)). 
 
One form of rate heterogeneity is known as heterotachy - which is an important process 
of protein evolution and a signature of functional divergence. Heterotachy comes from Greek 
language and refers to differences in speed (of mutations). The heterotachy model allows the 
mutation rate at a position to vary in different branches of the evolutionary tree and this 
phenomenon is routinely found among homologous sequences of distantly related organisms, 
where the homologous proteins have varying functions (Lopez et al., 2002). Statistical and 
empirical analyses have shown that variation within sites can influence phylogenetic tree making 
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(Lopez, et al., 1999; Philippe, et al., 2000; Gaucher et al., 2002). Some residues might be subject 
to altered functional constraints in various portions of a phylogenetic tree due to changes in the 
function of the protein and these changes in evolutionary conservation can misguide 
phylogenetic tree building algorithms. Figure 2.4 shows how this pattern is manifested at the 
protein sequence level. For example, a particular site is occupied by lysine and is thus slowly 
evolving or highly conserved within eukaryote eEF1A proteins. This same position within 
bacterial EF-Tu, however, is occupied by numerous amino acids. We therefore may conclude 
that there is a strong selective constraint acting on this site in eukaryotes but this constraint has 




Figure 2.4. An example of heterotachy at a particular site (aligned-position 153) in Elongation 
Factor gene family. Lysine is present universally in Eukaryotes whereas numerous amino acids 
occupy this site in Bacteria.  
 
There are three types (type-0, type-I, type-II) of functional divergence that are associated 
with site-specific rate shifts (Gu, 2001). These types are based on the assumption that sites which 
are important for function of a protein tend to be conserved throughout evolutionary history 
(Cole et al., 2010).  Type-0 represents conserved residues that are critical in function and are 
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shared by all members of a gene family. Type-I functional divergence represents amino acid 
configurations that are conserved in one portion of a phylogeny but variable in another portion of 
the phylogeny (also referred to as Heterotachy). Type-II functional divergence represents amino 
acid configurations that are conserved among all portions of a phylogeny but in which the exact 
amino acid is different among the portions of the tree (for example, positively charged residue 
versus negatively charged residue) 
Figure 2.5. Diagrams of site-specific patterns of functional constraints; type-0, type-I and type-II 
amino acid configurations. Type-0 functional divergence is universally conserved throughout the 
whole gene family. Type-I functional divergence in which a specific site is occupied by a 
conserved aspartic acid (D) residue in one linage of the tree but another linage is occupied by 
many different types of amino acids residues. Type-II functional divergence in which one lineage 
of homologous proteins is occupied by a conserved aspartic acid residue (D) while the other 
linage is also occupied by a conserved (but different) amino acid residue (glutamine, Q). 
(Modified from Cole and Gaucher, 2010) 
 
Predicting Functional Divergence 
In the present study, we analyzed such patterns of functional divergence at the protein 
level. We compared Elongation Factor (EF) proteins between the bacterial and eukaryotic 
domains of life. We identified type-I and type-II functionally divergent sites in the EF gene 
family and generated mutant variants in attempt to experimentally validate computational 
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predictions of heterotachy. To date, no such study has been published, thus we are under the 
assumption that this is a novel research direction and will provide biological explanations for 
patterns of sequence conservation/variability. 
 
Elongation Factor Tu 
Elongation Factor Tu (EF-Tu) is a bacterial GTP-binding protein composed of three 
structural domains (Kjeldgaard et al., 1996). EF-Tu is essential for translation in bacteria and its 
primary role is to bind and deliver the aminaoacylated-tRNA (aa-tRNA) complex to the A site of 
the ribosome during the elongation step of protein synthesis (Lodish, et al., 2008). Binding of the 
aa-tRNA complex to the ribosome, and subsequent disassociation, are fundamental steps for both 
efficient and accurate gene expression. This process is catalyzed by the formation of a EF-
Tu:GTP:aa-tRNA ternary complex. After binding to the A site of ribosome, GTP is hydrolyzed 
to GDP which leads to a conformational change (inactive form) in EF-Tu and results in the 
release of the EF molecule. In order to bind aa-tRNA, EF-Tu has to bind a GTP molecule and 
this enables the protein to adopt an active confirmation to accept the charged tRNA. To cycle 
between the active and inactive forms, EF-Tu requires a nucleotide exchange factor nucleotide. 
In bacteria, this exchange factor is called Elongation Factor Ts (EF-Ts) and it accelerates the rate 
of GDP release from a EF-Tu molecule in the inactive site. The unoccupied nucleotide binding 
site in the inactive EF-Tu is then available for GTP binding and this allows the protein to readopt 
the active confirmation. The nucleotide exchange mechanism itself begins with the binding of 
EF-Ts to EF-Tu:GDP complex and the reaction results in the ternary complex of EF-
Tu:GDP:EF-Ts complex. Due to the fact that this complex is unstable, GDP rapidly dissociates 
from the complex and GTP binds to the EF-Tu:EF-Ts complex due to the higher affinity of GTP 
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over GDP within the nucleotide binding site. The nucleotide exchange reaction is completed with 
the dissociation of EF-Ts from EF-Tu:GTP:EF-Ts and the final complex remains as EF-Tu:GTP.  
EF-Ts interacts with EF-Tu at the surface of domain-1 and domain-3. The N terminal domain of 
EF-Ts interacts with domain-1 of EF-Tu, whereas the C terminal of EF-Ts interacts with 





Figure 2.6. Structural organization of EF-Tu (bacteria) and eEF1A (eukarytoes). A) The 
structure of EF-Tu (Red) from E.coli binds to its nucleotide exchange factor EF-Ts (Green). EF-
Tu has three domains and EF-Ts binds in domain 1 and 3. B) The structure of eEF1A(Cyan) 
from S. cerevisiae bound to eEF1B (Yellow). eEF1A has three well defined domains just as EF-
Tu (indicative of their homologous relationship). Domain I binds GTP, domain II is proposed to 
bind the aminoacyl end of the aa-tRNA, and domains II and III are linked to actin binding. The 
nucleotide exchange factor in eukaryotes called eEF1B binds eEF1A in domains I and II. The 
numbers 1–3 represent the different domains of the proteins. The figures were prepared with 
Pymol using Protein Data Bank (PDB) 1F60 (The Yeast Elongation Factor Complex 





Elongation Factor 1A 
Eukaryotic elongation factor 1A (eEF1A) is a eukaryotic GTP-binding protein and 
homolog of the bacterial protein EF-Tu (Figure 2.7.). eEF1A thus has a major role in protein 
synthesis in eukaryotes. The overall properties of eEF1A are analogous to EF-Tu since they are 
homologous proteins. Some features, however, are different. eEF1A interacts with actin 
filaments and is thought to use actin as a track system as its shuttles tRNAs to and from the 
nuclease and a ribosome. Like EF-Tu, eEF1A has to be reactivated with GTP before binding 
another aminoacylated tRNA. The activation reaction, however, is catalyzed by binding the 
nucleotide exchange factor eEF1B which is not homologous with EF-Ts from bacteria. Recent 
studies have shown that the nucleotide exchange mechanism of eEF1A is fundamentally 
different from of that EF-Tu (Andersen et al., 2001). eEF1B interacts with domains 1 and 2 of 
eEF1A by disrupting the switch 2 region of eEF1A (Figure 2.6) and inserting a lysine in the 
Mg
2+
 binding site of the GDP/GTP binding site in domain 1 of eEF1A.  Conversely, in bacteria, 




 Score =  154 bits (389),  Expect = 5e-42, Method: Compositional matrix 
adjust. 
 Identities = 133/441 (30%), Similarities = 199/441 (45%), Gaps = 60/441 
(14%) 
 
Query  8    RTKPHVNVGTIGHVDHGKTTLTAAI--------TTVLAKTYGGAARAFDG-------IDN  52 
            + K H+NV  IGHVD GK+T T  +           + K    AA    G       +D  
Sbjct  3    KEKSHINVVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAELGKGSFKYAWVLDK  62 
 
Query  53   APEEKARGITINTSHVEYDTPTRHYAVVDCPGHADYVKNMITGAAQMDGAILVVAATDGP  112 
               E+ RGITI+ +  +++TP     V+D PGH D++KNMITG +Q D AIL++A   G  
Sbjct  63   LKAERERGITIDIALWKFETPKYQVTVIDAPGHRDFIKNMITGTSQADCAILIIAGGVGE  122 
 
Query  113  MP-------QTREHILLGRQVGVPYIIVFLNKCDMVD-DEELLELVEMEVRELLSQYDFP  164 
                     QTREH LL   +GV  +IV +NK D V  DE   + +  E    + +  +  




Query  165  GDDTPIV-----RGSALKALEGDAEW--------EAKILELAGFLDSY--IPEPERAIDK  209 
                P V      G  +     +A W        +A +++    L++   I +P R  DK 
Sbjct  183  PKTVPFVPISGWNGDNMIEATTNAPWYKGWEKETKAGVVKGKTLLEAIDAIEQPSRPTDK  242 
 
Query  210  PFLLPIEDVFSISGRGTVVTGRVERGIIKVGEEVEI--VGIKETQKSTCTGVEMFRKLLD  267 
            P  LP++DV+ I G GTV  GRVE G+IK G  V     G+    KS    VEM  + L+ 
Sbjct  243  PLRLPLQDVYKIGGIGTVPVGRVETGVIKPGMVVTFAPAGVTTEVKS----VEMHHEQLE  298 
 
Query  268  EGRAGENVGVLLRGIKREEIERGQVL--AKPGTIKPHTKFESEVYILSK--DEGGRHTPF  323 
            +G  G+NVG  ++ +  +EI RG V   AK    K    F + V +L+        ++P  
Sbjct  299  QGVPGDNVGFNVKNVSVKEIRRGNVCGDAKNDPPKGCASFNATVIVLNHPGQISAGYSPV  358 
 
Query  324  FKGYRPQFYFR------TTDVTGTIELPEGVEMVMPGDNIKMVVTLIHPIAMDDGL----  373 
               +      R        D     +L +  + +  GD   +      P+ ++        
Sbjct  359  LDCHTAHIACRFDELLEKNDRRSGKKLEDHPKFLKSGDAALVKFVPSKPMCVEAFSEYPP  418 
 
Query  374  --RFAIREGGRTVGAGVVAKV  392 
              RFA+R+  +TV  GV+  V 
Sbjct  419  LGRFAVRDMRQTVAVGVIKSV  439 
 
Figure 2.7. Comparison of sequence similarity between EF-Tu from E. coli and eEF1A from S. 
cerevisiae. Max score 154, total score 154, query coverage 97%, E value 5e-42. Query (EF-Tu), 
Sbjct (eEF1A). 
 
In addition to an important role in protein synthesis, studies have shown that eEF1A has 
several other activities, including interactions with the actin cytoskeleton (as mentioned above) 
(Gross et al., 2005), lipotoxic cell death (Borradaile et al., 2006), ubiquitin-dependent 
degradation of N-acetylated proteins (Gonen et al., 1994), and quality control of newly 
synthesized proteins (Hotokezaka et al., 2002). 
Although the structures of the eEF1A and EF-Tu are slightly different, they share the 
same mechanism of disruption within the Mg
2+
 coordination center of the nucleotide exchange 
factors eEF1B and EF-Ts, again, which are not homologous proteins. Despite intense efforts and 
large interest in understanding these patterns, we are the first to experimentally validate concepts 
that attempt to directly connect heterotachy to functional divergence among homologous 
proteins. Our research attempts to mutate specific sites in order to manipulate the abilities of 
these elongation factors (Tu and 1A) to bind wild-type nucleotide exchange factors from either 
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their cognate domain of life or the exchange factor from the other domain of life. We have used 
EF sequences from thirteen bacterial species and seventeen eukaryotic species (Figure 2.8.). To 
analyze these sequences, we used the DIVERGE (Detecting Variability in Evolutionary Rates 
among GEnes) program which identifies site-specific rate shifts using a multiple sequence 
alignment of amino acids in combination with a phylogenetic tree (Gu and Kent, 2001). Site-
specific statistical analysis was based on their posterior probability (PP) to determine critical 
amino acids residues for type-I and type-II functional divergence. We also applied cut-off values 
in attempt to better understand how the posterior probability associated with whether a site 




Figure 2.8. The tree used as input for DIVERGE from which the bacterial and eukaryotic 
clusters were selected. EF-Tu/eEF1A protein phylogeny roots the universal tree between bacteria 













The DIVERGE results were analyzed in the context of a 3D structure using Pymol 
software. The posterior probability (PP) cut-off we chose to select sites to mutate with EF-Tu or 
eEF1A were; 
a)  Sites predicted to have experienced Type-1 functional divergence in which the PP ≥ 0.9  
b)  Sites predicted to have experienced Type-1 functional divergence in which the PP ≥ 0.80 
c)  Sites predicted to have experienced Type-1 functional divergence in which the PP ≥ 0.80 + 
sites predicted to have experienced Type-2 functional divergence 
These sites were analyzed in the context of the crystal structures of Tu and 1A, and the sites 
within 5 Angstroms of the nucleotide exchange factors were selected to be swapped between Tu 
and 1A experimentally. Using these conditions, we hypothesized that generating these mutations 
would knockout EF-Ts binding for EF-Tu and knockin eEF1B binding into EF-Tu. The converse 
















2.2. MATERIALS AND METHODS 
Materials 
Escherichia coli strains and genotypes 
Tuner (DE3) pLysS Competent Cells (Novagen): The Tuner strain is a mutant form of K12, 
which contains the lac permease mutation (lacZY) that allows adjustable levels of protein 
expression by permitting entry of IPTG into the cells. The Tuner strain has pLysS plasmid which 
affects cell growth and viability by stabilizing recombinants encoding target proteins. Genotype: 
F
–




) gal dcm lacY1(DE3) pLysS (Cam
R
). Antibiotic resistance: 
Chloramphenicol and Carbenicilin. 
NovaBlue Singles Competent Cells (Novagen): The NovaBlue cell is a K-12 strain of E.coli, 
which provides high yields of plasmid DNA. These competent cells are used for plasmid 














C41 (DE3) pLysS Chemically Competent Cells (Lucigen): These cells are usually preferred 
due to their tolerance to toxic proteins. In this study, the purpose of using these cells was to 
express recombinant proteins that usually form inclusion bodies in the Tuner cells. Also, these 
cells effected protein purity for some variants. Antibiotic resistance: Chloramphenicol. 





pET-15b (Novagen): This vector contains a T7 promoter and a N-terminal His-Tag which is 
followed by a thrombin cleavage site. This vector was used for cloning and expression of 
nucleotide exchange factors. 
pET-21a (Novagen): This vector contains a T7 promoter and a C-terminal His-Tag  sequence. In 
this study, this vector used for cloning and expression of EF-Tu and eEF1A variants. 
pET-41a (Novagen): This vector contains T7 promoter and both GST-Tag and His-Tag 
sequences. Also, the vector has thrombin and enterokinase cleavage sites. Antibiotic resistance: 
Kanamycin. Purpose of using this vector was increase solubility. 
pET-43.1a (Novagen): This vector contains T7 promoter and 491 amino acids Nus-Tag protein. 
The vector also contains His-Tag and S-tag sequences which are followed by thrombin and 
enterokinase cleavage sites, respectively. The purpose of using this vector was to increase 
solubility due to the  large Nus-Tag sequence. 
General Medias and Buffers 
 LB (Luria-Bertani) Media: 0.5% yeast extract, 1 % tryptone, 0.5 % NaCl, and 1.5% agar for 
plates. 
YETM:  0.5% yeast extract, 1 % tryptone, 1% magnesium Sulfate heptahydrate (MgSO4•7H2O), 
and 1.5% agar for plates. Adjust to pH 7.5 with KOH. 
TFB1: 30mM potassium acetate (KOAc), 100mM Rubidium chloride (RbCl), 10mM 
CaCl2•2H2O, 50mM MnCl2•4H2O, and 15% Glycerol. Adjust to pH 5.8 with 0.2 M acetic acid. 
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TFB2: 10mM MOPS, 75 mM CaCl2-2H2O, 10mM RbCl, and 15% Glycerol. Adjust to pH 6.5 
with KOH.  
YPD medium and plates: 1% yeast extract, 2% peptone, 2% dextrose (D-glucose), and 2% agar 
for plates. 
10XTBE Buffer: 10.8% Tris base, 5.5% Boric acid, and 0.93% EDTA 
10XSDS (Sodium Dodecyl Sulfate) Buffer: 3.3 % Tris Base, 14.4 % Glycine, and 1% SDS 
Fairbanks Gel Staining/Destaining Solutions: A (0.05% Coomassie, 25% isopropanol, 10% 
acetic acid). B (0.005% Coomassie, 10% isopropanol, 10% acetic acid). C (0.002% Coomassie, 
10% acetic acid). D (10% acetic acid). 
Genes and Primers 
The genes that were used in this study were synthesized by DNA2.0 Inc. and Genewiz 
Inc. Synthetic PCR primers were purchased from Integrated DNA Technologies (IDT) Inc. 
Primers were used for subcloning into different vector. The genes and primers were diluted up to 
100 μM and stored at -20 °C.  
 
Methods 
Preparation of Competent Cells 
The purchased frozen cells were streaked onto a YETM plate and incubated at 37 °C. A 
single colony from YETM plate was inoculated into 5 mL of YETM medium and incubated for 
overnight. The overnight culture was diluted into 250 mL YETM medium and incubated for 2 hr 
with agitation, followed by additional 15 min incubation on ice. The cells were collected by 
centrifugation at 2,000 rpm at 4 °C and resuspended in 10 mL of TFB1 buffer. After 5 min 
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incubation on ice, the centrifugation step was repeated and the pellet was resuspended in 2 mL of 
TFB2 buffer and incubated on ice for 15 min. The competent cells were stored at -80 °C in 
microcentrifuge tubes.  
Subcloning EF-Ts and eEF1B 
Initially, we received our EF-Ts and eEF1B genes in the pET21a vector, which contains a 
His-Tag sequence at the carboxy terminus of the gene. We wanted to remove His-Tag sequence 
with a thrombin cleavage site. The following primers were used for subcloning from pET21a to 
pET15b. 
Amplifying forward primer: 5‟TAATACGACTCACTATAGGGGAAT3‟  
Amplifying EF-Ts reverse primer: 5‟GTGCTCGAGTTAGCTCTGCTT3‟   
Amplifying eEF1B reverse primer: 5‟GTGCTCGAGTTACAATTTCTGCAT3‟  
Basically, pET21a was used as template and the target region was amplified by PCR under 
standard conditions. After gel purification of amplified-DNA, both insert and pET15b vector were 
double digested with NdeI and XhoI (NEB) restriction enzymes for overnight at 37 °C. Standard 
ligation and chemical transformation protocols were applied. The enzymes used for ligation was 
purchased from New England Biolabs (NEB). 
Recombination PCR 
PCR reactions were performed with Taq polymerase and optimized for PCR yield unless 
otherwise specified. The conditions are summarized in Table 2.1. 
 
Table 2.1: General PCR cycling parameters for subcloning. Annealing temperature vary 
depending on variant and primers.  
 
Component Final Concentration Volume/25μL rxn 
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Water  14.25 μL 
5X Go Taq colorless Buffer 5X 5 μL 
dNTPs 10mM 0.5 μL 
Amplify forward primer 10 μM 2 μL 
Amplify reverse primer 10 μM 2 μL 
Template plasmid DNA 20 ng/μL 1 μL 











QIAgen Gel Extraction Protocol 
Fragments of DNA generated by PCR reactions were separated using standard DNA 
electrophoresis (0.8 % agarose gel). DNA bands corresponding to desired products were 
identified using a UV transilluminator and bands were excised from EtBr-stained gels using a 
scalpel. Separation of DNA from gel was achieved using the QIAgen Gel Extraction Kit and 
protocols supplied by the manufacturer (QIAgen). Basically, the gel slice was weighted in a 1.5 
mL microcentrifuge tube and mixed with 3 volumes of QG buffer, containing guanidine 
thiocyanate. Samples were incubated at 48 °C until the gel slice had completely dissolved and 
the optimal pH for DNA binding to the spin column was adjusted by using 3 M sodium acetate 
(pH 5.0). To increase the yield of DNA fragments, 1 gel volume of isopropanol was added to the 
Step  Time Temperature Cycles 
Initial Denaturation 3 min 95 °C 1X 
Denaturation 30 sec 95 °C  
34X Annealing 30 sec 52 °C 
Extension 90 sec 72 °C 
Final Extension 6 min 72 °C 1X 
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sample and mixed. The sample was applied to the column, provided by manufacturer, and 
centrifuged. The column was washed with PE buffer, containing ethanol, and the DNA was 
eluted with 50 μL sterile molecular grade water (PH 7.5).   To increase DNA concentration, the 
tube incubated with elution water for 3-5 min at room temperature prior to centrifugation. The 
eluted DNA was stored at –20 °C. 
Chemical Transformation 
The frozen competent cells were placed on ice to thaw. 10 μL of competent cells were 
mixed with 50 ng of plasmid DNA and incubated on ice to ensure an even distribution of DNA. 
Cells were heat-shocked at 42 °C water bath for 45 sec, following 2 min incubation on ice. 250 
μL of LB media was added to the cells and placed on shaker for 1 hr at 37 °C.  75 μL of 
transformation mixture was plated onto LB agar plates with a plasmid specific selective 
antibiotic and incubated at 37 °C for overnight.  
Analyzing Transformants 
Several single white colonies were taken from the selective plate and cultured 
individually in 4 mL LB media containing suitable antibiotic. The culture was placed in a 37 °C 
incubator with 250 rpm shaking for overnight.  
Plasmid DNA Purification 
 
The plasmid DNA was isolated using QIAprep Spin Miniprep Kit from QIAgen. The 
bacterial cells were transferred to a microcentrifuge tube and collected by centrifugation
*
 at room 
temperature. The pellet was resuspended in buffer P1 (lysis buffer and RNase-A), buffer P2 
(contains sodium hydroxide), and buffer N3 (contains guanidine hydrochloride, acetic acid), 
respectively. After cells lysate was clarified by centrifugation, the supernatant was loaded to a 
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QIAprep spin column and washed with buffer PE. The plasmid DNA elution was collected in a 
1.5 mL sterile microcentifuge tube with 50 μL sterile water. The concentration of the samples 
was determined using Nanodrop 1000 spectrophotometer, Thermo Scientific Inc. 
*
All centrifugation steps are carried out at 13,000 rpm (~17,900 x g) in a conventional, table-top 
microcentrifuge and all steps carried out at room temperature. 
Sequencing 
To confirm whether the DNA plasmids were cloned in the correct orientation, the 
samples were sequenced by Genewiz Inc. The samples were diluted to 50 ng/µL by using sterile 
water.  For each reaction, 10 µL of the plasmid DNA at 50 ng/µL provided in a labeled 0.2 mL 
PCR tube and cap.  
Expression and Purification of EF-Tu, EF-Ts, and eEF1B 
A single colony was inoculated into 3 mL of LB media and incubated for overnight at 37 
°C. The overnight culture of Tuner cells was diluted into a flask containing 250 mL of LB media, 
100 μg/mL carbenicillin, and 50 μg/mL chloramphenicol. The cells were grown at 37 °C to a 
density of 0.6 at A600 and then induced to a final concentration at 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG). The culture was incubated at 37 °C with agitating at 250 rpm for 
4 hr. The cells were collected by centrifugation at 4,500 x g for 20 min. The wet weight of the 
pellet was determined and stored at -80 °C until was resumed purification. 
The freezer cells were thawed at room temperature for 15 min and resuspended in 
BugBuster Protein Extraction Reagent (Novagen). The cell pellet was completely resuspended in 
BugBuster reagent by pipetting and gentle vortexing, using 5 mL BugBuster per gram of wet cell 
pellet. In most cases, 1 μL (25 units) of Benzonase (Novagen) was added per mL of BugBuster 
reagent to digest DNA and reduce sample viscosity. The cell suspension was incubated on a 
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shaking platform for 30 min at room temperature. The insoluble cell debris was removed by 
centrifugation at 10,000 × g for 30 min at 4 °C.  
The collected supernatant was transferred to a clean tube and the pellet was saved to 
analyze inclusion bodies. A Ni-NTA Spin Column (QIAgen) was equilibrated with Lysis Buffer 
(50 mM NaH2PO4, 500 mM NaCl, 5 mM MgCI2, and 5 mM imidazole, pH 7.6) and centrifuged 
for 2 min at 500 x g. The cleared lysate was loaded onto the pre-equilibrated Ni-NTA spin 
column and centrifuged. The column was washed three-five times with Wash Buffer (50 mM 
NaH2PO4, 500 mM NaCl, 5 mM MgCI2, and 50 mM imidazole, pH 7.6). The protein was eluted 
twice with Elution Buffer (50 mM NaH2PO4, 500 mM NaCl, 5 mM MgCI2, and 500 mM 
imidazole, pH 7.6). In all steps, the flow-through was saved for analysis by SDS-PAGE to check 
the stringency of the conditions. The purified protein was dialyzed against 50 mM Tric-HCI (PH 
7.8), 100 mM KCI, 1 mM DTT, and 3 mM MgCI2. 
Expression and Purification of EF-Tu Variants, eEF1A, and its Vriants 
A single colony was inoculated into 4 mL of LB media and incubated for overnight at 37 
°C. The overnight culture diluted in a flask containing 250 mL of LB medium, 100 μg/mL 
carbenicillin, and  50 ug/mL chloramphenicol. The cells were grown at 37 °C to a density of 0.6 
at A600 and then induced with 0.5-1 mM IPTG. The culture was incubated at 37 °C and agitated 
at 250 rpm for 6 hr. The cells were collected by centrifugation at 5,000 x g for 15 min. The wet 
weights of the pellet were determined and immediately purified or stored at -80 °C until needed. 
The freezer cells were thawed at room temperature for 15 min and resuspended in 8 M 
Urea; 100 mM NaH2PO4; 5 mM MgCI2; and 10 mM Tris-HCl (pH 8.0). The cell pellet was 
completely resuspended in buffer by pipetting and gentle vortexing. Cell lysis was achieved by 
64 
 
sonication and the suspension was incubated on a shaking platform for 2 hr at room temperature. 
The cell debris was removed by centrifugation at 10,000 × g for 30 min at room temperature.  
The supernatant was transferred to a clean tube and Ni-NTA Spin Columns (Qiagen) was 
equilibrated with Lysis Buffer (8 M Urea; 10 mM NaH2PO4; 5 mM MgCI2; and 10 M Tris-HCl 
(pH 8.0)) and centrifuged for 2 min at 600 x g. The cleared lysate was loaded onto the pre-
equilibrated Ni-NTA spin column and centrifuged. The column was washed three times with 8 
M Urea; 100 mM NaH2PO4; 5 mM MgCI2; and 10 mM Tris-HCl; 50 mM imidazole, pH 8.0. The 
elution was performed with 8 M Urea; 100 mM NaH2PO4; 5 mM MgCI2; 10 mM Tris-HCl; and 
300 mM imidazole, pH 8.0.  In all steps, the flow-through was saved for analysis by SDS-PAGE 
to check the stringency of the conditions.  
Refolding Denatured-Purified Proteins 
Denatured purified-protein was diluted two-fold in buffer of 50 mM Tris, 20 mM NaCI, 
100 mM KCI (pH=8.2), and then stepwise dialyzed against 2 M urea, 50 mM Tris-HCI, 20 mM 
NaCI, 100 mM KCI, (pH=8.2); 1 M urea, 50 mM Tris-HCI, 20 mM NaCI, 100 mM KCI, 
(pH=8.2); 0.5 M urea, 50 mM Tris-HCI, 20 mM NaCI, 100 mM KCI, (pH=8.2), respectively, by 
using Molecular weight cut-off (MWCO) dialysis cassette (Pierce).  
Removing His-tag from EF-Ts and eEF1B 
The His-tag was removed by using the Thrombin Cleavage Capture Kit (Novagen). 
Thrombin was diluted in 1:25 in Thrombin Dilution Buffer (50 mM sodium citrate, pH 6.5, 200 
mM NaCl, 0.1% PEG-8000, 50% glycerol) and mixed with target protein and 10X Thrombin 
Cleavage Buffer (200 mM Tris-HCl, 1.5 M NaCl, 25 mM CaCl2 (pH=8.4)). The mixture was 
incubated at 25 °C with agitation for 20 hr. Reactions were stopped with either protease inhibitor 
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complex or Streptavidin Agarose (50 % slurry in phosphate buffer, 0.02 % sodium azide 
(pH=7.5)) and incubated for an additional hr. The protein that still has His-tag was removed via 
loading on pre-equilibrated His-tag spin column. The flow through not containing His-tag was 
collected for analysis.  
Protein Quantification 
All the proteins used in binding assays were quantified by performing Bradford protein 
assay. Each sample was measured in triplicate. Basically, 1 mL of Bradford solution (Bio-Rad) 
was incubated at room temperature for 30 min and followed by the addition of 20 μL of sample 
protein. After 5 min incubation at room temperature, samples were transferred to a cuvette and 
absorption at 595 nm was plotted against a bovine gamma globulin concentration curve (Cary 50 
UV-Visible Spectrophotometer, Varian). 
 
Pull-Down Assay 
His-tagged eEF1A and EF-Tu variants were mixed with either eukaryotic (eEF1B) or 
bacterial (EF-Ts) nucleotide exchange factors (without His-tag) at a ratio of 1:1.5 and incubated 
at room temperature for 4 hr in buffer of 55 mM Tris-HCl (pH 7.8), 130 mM KCl, 20 mM NaCI, 
and 2 mM EDTA.  Before loading on the Ni
+2
-NTA column, samples were diluted two-fold in 
incubation buffer without EDTA. The dilution was done to prevent interference of EDTA with 
the column. The column was washed twice with buffer A containing 55 mM Tris-HCI (pH 8.2), 
20 mM NaCI, 10 mM KCI, 500 mM urea, and 10 mM imidazole, to remove nonspecific 
proteins. Finally, samples were eluted with buffer A containing 55 mM Tris-HCI (pH 8.2), 20 
mM NaCI, 10 mM KCI, 500 mM urea, and 300mM imidazole and analyzed by SDS-PAGE. 
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Native Gel Electrophoresis 
Native gel electrophoresis was performed at 4 °C (250 V, 1.5 hr) on 10% Tris-HCI 
polyacrylamide gel. The running buffer used contained 8 mM Tricine (pH 8.2) and 1 mM EDTA. 
To analyze the interactions between EF-Tu and EF-Ts, these proteins were mixed in a buffer that 
contained 50mM Tris-HCI (pH 7.8), 70mM KCI, 5mM EDTA, 1mM DTT, and 5% glycerol. 
After 2 hr incubation at room temperature, the mixture was mixed with a half volume of native 
gel sample buffer and then load on the native gel. The gel was stained with standard gel 





















2.3. RESULTS AND DISSCUSSION 
Despite intense efforts and interest in understanding patterns of functional divergence, no 
one has experimentally validated these concepts to date. To address this, we have mutated 
specific sites identified by our evolutionary analyses as being implicated in functional divergence 
between EF-Tu and eEF1A and their abilities to bind their respective nucleotide exchange 
factors. 
Detecting Functionally Divergent Sequences 
We performed DIVERGE software analysis to detect functional divergence among EF 
protein family members, based on site-specific rate shifts. Posterior probabilities of whether a 
site may have experienced type-I or type-II functional divergence guided us in our selection of 
amino acid residues believed to be responsible for functional divergence among this protein 
family. We used EFs sequences from 13 species in bacteria and 17 species of eukaryotes. Based 
on the DIVERGE analysis, residues predicted to have experienced type-I functional divergence 
between Tu and 1A homologs are highlighted in Figure 2.9. For example, positions 31, 34, 36, 
51, 64 etc. are occupied by a conserved glutamate in eukaryotes. Conversely, these same 
positions are occupied by various amino acids in bacteria and thus those sites are considered to 
be rapidly evolving across time. Other examples of functional divergence based on the 
DIVERGE analysis are positions 9 and 10 which are occupied by a conserved hydrophobic 
valine in eukaryotes while the same positions are occupied by other conserved but different 
amino acid glycine (hydrophobic) and threonine (hydrophilic), respectively. This distribution is 
the signature of type-II functional divergence between these two domains of life. Some sites (i.e. 
3, 5, 12, 13, 15, etc) that are thought to be critical in functions that are shared by all members of 
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the EF gene family (e.g., shuttling aa-tRNAs) are conserved in both domains of life, eukaryotes 











Figure 2.9: Sequence alignment of Eukaryotic and Bacterial EFs. Boxed positions represent type-
I functional divergence. Cut-off for posterior probability is 0.9. We used EFs sequences from 13 
different species in bacteria and 17 species from eukaryotes. Type-II sites are not highlighted but 
they are easily identifiable from patterns of amino acid replacements (e.g., position 371). 
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 Detecting mutated sites 
Pymol software was used to determine the distribution of functionally divergent sites across the 
three-dimensional structures of the proteins.  In Pymol, we aligned the 1EFU and 1F60 structures 
to identify sites that were within 5 Angstroms of the opposite nucleotide exchange factor (e.g., 
sites on EF-Tu that would be with 5 Angstroms if eEF1B were to bind EF-Tu, and conversely for 
eEF1A). Sites to mutate were selected based on the DIVERGE analysis using parameters and 
cutoffs summarized in table 2.2.   
Table 2.2: Considered statistical support and parameters to generate mutant variants. All cut-offs 
within 5 Angstroms of respective nucleotide exchange factor.  
Eukaryotic background (eEF1A) 




Conditions and Cutoffs 
Knockout eEF1B 
 
E1A Type 1 Divergence with PP ≥ 0.9 
E1B Type 1 Divergence with PP ≥ 0.80 
E1C Type 1 Divergence with PP ≥ 0.80 + Type 2 
Knockin EF-Ts 
 
E2A Type 1 Divergence with PP ≥ 0.9 
E2B Type 1 Divergence with PP ≥ 0.80 
E2C Type 1 Divergence with PP ≥ 0.80 + Type 2 
Knockout eEF1B/Knockin EF-Ts 
 
E3A Type 1 Divergence with PP ≥ 0.9 
E3B Type 1 Divergence with PP ≥ 0.80 
E3C Type 1 Divergence with PP ≥ 0.80 + Type 2 
Bacterial background (EF-Tu) 




Conditions and Cutoffs 
Knockout EF-Ts 
 
B1A Type 1 Divergence with PP ≥ 0.9 
B1B Type 1 Divergence with PP ≥ 0.80 
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 B1C Type 1 Divergence with PP ≥ 0.80 + Type 2 
Knockin eEF1B B2A Type 1 Divergence with PP ≥ 0.9 
B2B Type 1 Divergence with PP ≥ 0.80 
B2C Type 1 Divergence with PP ≥ 0.80 + Type 2 
Knockout EF-Ts / Knockin 
eEF1B 
 
B3A Type 1 Divergence with PP ≥ 0.9 
B3B Type 1 Divergence with PP ≥ 0.80 




We generated mutant variants of EF-Tu and eEF1A based on the combination of 
DIVERGE results and location on protein structure. The number of mutated sites within a variant 




Figure 2.10a: Sequence alignment of eEF1A variants. (Abbreviations: KO: Knock out, KI: 







Figure 2.10b: Sequence alignment of EF-Tu variants. (Abbreviations: KO: Knock out, KI: 
Knock in) 
 
Subcloning EF-Ts and eEF1B 
Full length EF-Ts and eEF1B were subcloned into an N-terminal 6x-Histidine tag vector with 
a thrombin cleavage site, pET15b (Novagen), at the NdeI and XhoI (NEB) restriction sites. The 
construct was transformed into an E. coli Novablue strain for propagation. Desired DNA sequences 
were verified by sequencing (Genewiz) and then transformed into the E. coli Tuner strain for 
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expression. Carbenicillin was used to select pET15b in Nova blue strain and both carbenicillin and 
chloramphenicol were used to select the Tuner strain. 
Expression and Purification of EF-Tu, EF-Ts, and eEF1B 
To investigate the interaction of EF-Tu and eEF1A variants for nucleotide exchange 






Figure 2.11: SDS-PAGE gel analysis of purified-recombinant EF-Tu, EF-Ts, and eEF1B 
proteins. The genes were expressed in E. coli and extracts were prepared under native conditions. 
This figure shows various purification steps using a Ni
2+ 
column. Each of these proteins contain 
a N-terminal or C-terminal 6XHis-tag for Ni-Affinity chromatography. M represents protein 
standard marker (Kaleidoscope, BioRad). Lanes numbered 1 to 7 represent; crude cell lysate (1), 
flow-through after loading the sample onto a Ni
2+ 
column (2), three-wash steps (3-5), two elution 
steps (6-7).   
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His-tagged derivative Bacterial (EF-Ts) and Eukaryotes (eEF1B) nucleotide exchange 
factor and EF-Tu were successfully expressed in E. coli and purified under standard native 
conditions (Figure 2.11). Expressed-proteins contain C-terminal 6XHis-tag for Ni-affinity 
chromatography, so purity of these proteins was achieved by using imidazole and salt gradient.  
From SDS-PAGE analysis the molecular weight for EF-Tu, EF-Ts, and eEF1B were roughly 
determined as 45 kD, 33 and 30, respectively.  To remove all of unspecific proteins, a number of 
wash steps were conducted and an imidazole gradient was applied during elution.  
 
Expression and Purification of EF-Tu Variants, eEF1A, and its Variants under Denaturing 
Conditions 
Initially, a series of alternative conditions were attempted to improve expression and purification 
of insoluble eEF1A and the majority of the variant proteins. These conditions included varying 
growth and induction temperature, IPTG concentration, adjusting osmotic stress (inducing with 
Ethanol and Sucrose or Magnesium Chloride), expressing in different vectors (pET43.1a and 
pET41a) and strains (C41 and C43 cells), expressing with yeast vectors (pYES2⁄NT A, B, C and 
pPink-HC & pPink-LC) and strains (INVSc and PichiaPink strain 1, 2, 3, 4), addition of other 
reagents in resuspension buffer including solubilzing agents such as 1% SDS and 2% Triton, 
Arginine, etc. We applied all of these conditions to most of the 18 mutant EF-Tu and eEF1A 
variants because we were hoping that some of those proteins might respond at least to one of 
these experimental conditions. Despite consuming over a year to get soluble proteins, 
unfortunately none of the attempted modifications improved the protein solubility (data not 
shown). Subsequently, we solubilized the target proteins with either 8M urea or 6M guanidine 
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and a variety of alternate conditions were used to optimize this purification procedure including 
higher salt concentrations and an imidazole gradient (see materials ant methods section).  
 
Refolding Purified Protein 
We have purified EF-Tu variants, eEF1A, and its variants, under denaturing conditions 
using 8M urea. Because denatured protein is not functional, it has to be refolded correctly before 
conducting structural and functional studies. We successfully refolded denatured proteins via a 
stepwise dilution and dialysis procedure to remove denaturing agents (see materials and methods 
section). Protein properties were determined by their ability to bind to nucleotide exchange 
factors. Results are shown in figure 2.14. 
Removing His-tag from EF-Ts and eEF1B 
Thrombin recognizes the consensus sequence Leu-Val-Pro-Arg-Gly-Ser and cleaves the 
peptide bond between Arg and Gly. This consensus sequence is utilized in pET15b vectors and 
allowed us to remove the His-tag from purified EF-Ts and eEF1B proteins (the His-tag was 
maintained on EF-Tu and eEF1A, and their variants, for purposes of immobilization during the 
pull-down binding assays). His-tag was removed using a Thrombin Cleavage Capture Kit 
(described in materials and methods). We kept some non-cleaved protein as a control and 
separated the cleaved protein from any non-cleaved protein by loading the reaction on a Ni-NTA 
column. The cleaved protein flowed through and the non-cleaved protein bound to the column 
and then eluted with imidazole for SDS-PAGE gel analysis (Figure 2.12). The cleaved protein 
was 2 KDa smaller in molecular weight than non-cleaved protein. To confirm the complete 
removal of His-tag protein, flow through from Ni
2+
 column was loaded onto fresh column and 
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eluted with imidazole. SDS-PAGE results confirm that EF-Ts (Figure 2.12) and eEF1B (data not 
shown) were free from His-tags. 
 
 
Figure 2.12: SDS-PAGE gel analysis of thrombin cleavage of EF-Ts. Purified N-terminal 
6XHis-tag EF-Ts cleaved by thrombin. The cleavage reaction passed-through a Ni
2+
 column 
twice to remove all noncleaved EF-Ts. M represents marker to compare molecular weight of 
each protein (Kaleidoscope, BioRad). Numbers 1 to 7 represent; purified EF-Ts protein (1), first 
flow-through of cleaved EF-Ts after loading the sample onto a Ni
2+ 
column (2), wash for 
nonspecific binding (3), elution (4), flow-through of number 2 (5), wash (6), elution (7).   
 
Interaction between EF-Tu:EF-Ts and eEF1A:eEF1B 
To assess whether mutant variants bind to the nucleotide exchange factors, we first 
looked at the interaction between wild type EF-Tu:EF-Ts and eEF1A:eEF1B. We performed 
native gel analysis, SDS PAGE, and size exclusion chromatography analysis to assess 
interactions between these pairs. 
Interaction between EF-Tu:EF-Ts : Native Gel Analysis 
The binding of recombinant bacterial EF-Tu to recombinant EF-Ts proteins was analyzed 
by native PAGE gel. In the absence of EF-Ts, a small amount of EF-Tu penetrated into the gel 
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while a majority stayed in the wells of the gel (Figure 2.13). This may be due to oligomerization 
of EF-Tu – a process known from the crystal structures of EFs. In contrast, when EF-Ts was 
present, complexes were formed and migrated into the gel. Perhaps, binding EF-Ts prevents 
oligomerization of EF-Tu. The complexes between bacterial EF-Tu and EF-Ts molecules were 
further confirmed by pull-down assays and size exclusion chromatography. SDS-PAGE analysis 
clearly revealed the presence of a EF-Tu:EF-Ts complex (Figure 2.14 and 2.15). These results 
served as a control while comparing binding abilities of nucleotide exchange factors to other 
variants of EF-Tu and eEF1A.  We also tried to analyze the eEF1A:eEF1B complex on native 
gel but we were not successful because eEF1A has a very high isoelectric point of 9.1. Due to 
this high isoelectric point, penetration of eEF1A into the native gel was probably prohibited . 
However, the complexes between eEF1A and eEF1B molecules were confirmed by pull-down 







Figure 2.13: Native gel analysis of interactions between EF-Tu and EF-Ts.  The ability of EF-Tu 
to bind to EF-Ts was analyzed by10% Tris-HCl native gel, run for 2 hr at 250V. Tu:Ts 
complexes formed just above EF-Ts. Without EF-Ts, EF-Tu stayed in the well, possibly due to 
the oligomerization of EF-Tu molecules. The addition of EF-Ts to EF-Tu caused the EF-Tu 
bands to disappear and a new band containing the EF-Tu:EF-Ts complex to appear slightly 
above the EF-Ts band.  
 
 
Interaction between EF-Tu:EF-Ts and eEF1A:eEF1B : Size Exclusion 
Chromatography 
The association between EF-Tu:EF-Ts and eEF1A:eEF1B were also demonstrated using 
a size-exclusion column. Molecules were separated based on their size. EF-Tu:EF-Ts comlexes 
came off the column first and then followed by EF-Ts. We did not observe EF-Tu alone because 
most of the EF-Tu participated in EF-Tu:EF-Ts complexes thus only a small portion of EF-Tu 
was observed in the second peak.   
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Figure 2.14: Interaction between E. coli EF-Tu:EF-Ts complexes analyzed by HiPrep Superdex-
200 size-exclusion column chromatography. Circled area in each peak was concentrated by 
Trichloroacetic acid (TCA) precipitation and then analyzed by SDS-PAGE. The left peak 
represents the EF-Tu:EF-Ts complex (I), the right peak shows the EF-Ts molecule without a His-
tag. 
 
The complexes formed between recombinant Saccharomyces cerevisiae eEF1B and 
eEF1A efficiently revealed by size-exclusion column chromatography using a HiPrep Sephacryl 
S-200 column (Figure 2.15). The three peaks on the size-exclusion chromatograms for eEF1A 
and eEF1B were analyzed by SDS-PAGE and the presence of eEF1A:eEF1B complex was 
demonstrated in the middle peak (II). Separation between II and III picks were poor but SDS-
PAGE analyzes revealed clear data. Some portion of eEF1A came off first, this could be because 
of not complete refolding of eEF1A or the interaction conditions weren‟t optimum. 
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Figure 2.15: Interaction between Saccharomyces cerevisiae eEF1A:eEF1B complexes analyzed 
by HiPrep Sephacryl S-200 size-exclusion column chromatography. Circled-area in each pick 
was concentrated by TCA precipitation prior to analyze on SDS-PAGE. The first pick 
demonstrates eEF1A (I), the second pick shows eEF1A:eEF1B complex (II), and the right pick 
represents eEF1B molecule (III). 
 
Interaction between EF-Tu:EF-Ts and eEF1A:eEF1B : Pull-Down Assay 
Interactions between wild-type (EF-Tu:EF-Ts and eEF1A:eEF1B) and mutant variants 
were next monitored by performing pull-down assays. We were able to pull-down EF-Ts using a 
His-tagged EF-Tu as well as pull-down eEF1A using a His-tagged eEF1B (Figure 2.16). When 
we loaded EF-Tu or eEF1A onto the column, nearly all of the protein bound to the column based 
on high purity and the presence of a His-tag. However, when EF-Ts or eEF1B was loaded onto 
the column, nearly 50% of the protein came off with the flow-through because these proteins 
lack a His-tag and the portion that stayed in the column was the portion that bound to EF-Tu or 
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eEF1A. EF-Tu:EF-Ts complexes were eluted with a high amount of imidazole. The same 
experiment was performed for eEF1A:eEF1B complexes and their variants.  
 
 
Figure 2.16: SDS-PAGE analysis of binding interactions between EF-Tu:EF-Ts and 
eEF1A:eEF1B. His-tagged purified EF-Tu incubated with EF-Ts (no His-Tag) and passed 
through a Ni
2+
 column. Non-specific interactions were removed by washing the column and then 
the EF-Tu:EF-Ts complex was eluted with a high amount of imidazole. The same experiment 





Binding ability of EF-Tu Variants to EF-Ts or eEF1B 
Binding abilities of EF-Tu variants were determined by pull-down assays. Binding ability 
EF-Tu was analyzed in three independent steps; knock-out EF-Ts, knock-in eEF1B, and  knock-
out EF-Ts + knock-in eEF1B. Each step was based on three statistical parameters and structural 
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analysis. Therefore we had nine variants in total for each domain of life to be analyzed. 
Parameters are summarized in table 2.2. First we analyzed knock-out of EF-Ts from EF-Tu 
(based on heterotachous sites) and monitored the binding ability of EF-Tu to the nucleotide 
exchange factors (Figure 2.17A). EF-Ts was mostly knocked out from EF-Tu and some small 
portion of EF-Ts remained bound, but the bands get thinner if we compare this to the interaction 
between wild-type EF-Tu:EF-Ts. EF-Tu was also able to bind to eEF1B for these variants 
despite the fact that we did not engineer these variants to bind eEF1B. Such an intrinsic property 
is probably dictated by sites that have overlapping functions in EF-Tu and eEF1A in their 
abilities to bind their respective nucleotide exchange factors. 
In the second step, we determined the ability to knock-in binding of eEF1B into EF-Tu. 
In this case, EF-Tu sites in proximity to eEF1B according to the overlay of the EF-Tu/eEF1B 
superimposition of 3D-structures and having statistically significant predictions according to 
DIVERGE were replaced with residues from the eukaryotic eEF1A. The amount of eEF1B that 
interacts with EF-Tu variants increased relative to the amount of eEF1B that can bind to wild-
type EF-Tu. Interaction between EF-Tu:EF-Ts relatively decreased while compare to the wild-
type interaction of EF-Tu:EF-Ts. Reduction in EF-Ts binding could be because of some 
mutations to knock-in eEF1B interfered with EF-Ts binding sites (Figure 2.17B).  
In the third step, we replaced EF-Tu sites with eukaryotic background to create both 
knock-out EF-Ts and knock-in eEF1B. The binding ability of eEF1B to EF-Tu variants had 
gradually increase in comparision of the first and second steps. The small amount of EF-Ts 
remained bound to EF-Tu (Figure 2.17C). These results indicate that site-specific rate shift is an 












Figure 2.17. SDS-PAGE gel analysis of binding ability of nucleotide exchange factors to 
EF-Tu variants. His-tagged EF-Tu variants were mixed with either eukaryotic (eEF1B) or 
bacterial (EF-Ts) nucleotide exchange factors (with no His-tag) and incubated at room 
temperature for 4 hr and then passed-through Ni
2+
 column. To remove all non-specific 
interactions, the column was washed with a buffer prior to the elution. In the gel, top line 
represents EF-Tu variants and bottom line represents nucleotide exchange factors (EF-Ts, 
eEF1B). A) Knock-out EF-Ts from EF-Tu variants. B) Knock-in eEF1B into EF-Tu. C) Knock-
out EF-Ts + Knock-in eEF1B into EF-Tu.  For abbreviations, see table 2.2.  
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Binding ability of eEF1A Variants to EF-Ts or eEF1B 
Binding ability of eEF1A variants were also determined by pull-down assay and the same 
parameters were used, as well. Knocking out of eEF1B from eEF1A results revealed that eEF1B 
was partially knocked-out and the rest of the protein remained bound to eEF1A, but the intensity 
of the bands were low while compare to the wild-type interaction of eEF1A:eEF1B. Conversely, 
no interaction of eEF1A:EF-Ts was observed and this also validate that there is no background 
interaction between these two proteins (Figure 2.18A).  
When we knocked-in EF-Ts into eEF1A, we observed some bands that indicate the 
ability of EF-Ts to bind eEF1A (Figure 2.18B).  
The knocking out eEF1B plus knocking in EF-Ts results demonstrated that EF-Ts 
showed great dependency to eEF1A. The amount of EF-Ts that bound eEF1A had greately 















Figure 2.18. SDS-PAGE gel analysis of binding ability of nucleotide exchange factors to eEF-
1A variants. His-tagged eEF1A variants were mixed with either eukaryotic (eEF1B) or bacterial 
(EF-Ts) nucleotide exchange factors (with no His-tag) and incubated at room temperature for 4 
hr, and then passed-through Ni
2+
 column. Non-specific interactions were washed off with a 
buffer prior to the elution. In the gel, top line represents eEF1A variants and bottom line 
represents nucleotide exchange factors (EF-Ts, eEF1B). A) Knock-out eEF1B from eEF1A 
variants.  B) Knock-in EF-Ts into eEF1A.  C) Knock-out eEF1B + Knock-in EF-Ts into eEF1A. 





We have experimentally validated site-specific rate shifts (type-I, type-II functional 
divergence) in the EF protein family. We used the power of statistical analysis and synthetic 
biology to engineer elongation factors to bind the non-cognate exchange factor in the other 
domain of life and vice-versa for bacteria and eukaryotes.  
These findings may enable us to make functional inferences and explanations about 
minor functional diversification among EF-Tu and eEF1A because conservative in one site of a 
homologous proteins may acquire a new function, or becoming more variable may lead to a lose 
in function. In addition, our results confirm that heterotachy is a important pattern to generate 
functional diversity during the evolution of protein families.  
Although the structures of eEF1A and EF-Tu are slightly different, they share similar 
mechanisms in their interactions with their cognate nucleotide exchange factors eEF1B and EF-
Ts, which are not themselves homologous. When we look at the binding ability of nucleotide 
exchange factors to the variant, eEF1B did not display large variation in terms of binding EF-Tu. 
This could be because the sites where eEF1B interacts with eEF1A are conserved in both 
domains of life and eEF1B has some background interactions with wild-type EF-Tu. Conversely, 
EF-Ts showed large variability it is ability to bind to  eEF1A variants.  
For future directions, crystallizition of some of the interactions between variants and 
nucleotide exchange factors would be valuable. This would provide us with a unique opportunity 
to further dissect molecular interactions that enable functional divergence.  
In total, we have shown how an evolutionary synthetic biology can both generate 
biomolecules potentially useful for biomedicine and exploit evolutionary models to guide the 
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List of Sequences for Knock-out variant 
design  
    Sites with greatest statistical support  from Diverge Analsysis that are within 
  5 Angstromes of respective nucleotide exchange factors  
   
 




# Type I (Gu 99 & 01) & Type II Type I (Gu99 &01)  
 
DIVERGE Results 
10 16THR V 
 
Color PP 
23 29ALA G 
 
  100-90 
26 32THR D 
 
  89-80 
27 33THR K 
   31 37LYS E 
 
Type II Diverge 
36 42A E 
 
  59.847 
37 43A F 
 
  19.75 
38 44R K 
   39 45A Y 
 
Other Residue 
40 46F A 
 
  
 41 47D W 
   42 48Q V 
   43 49I L 
   45 51N K 
   47 53P 64LYS 
   48 54E A 
   50 56K 67ARG 
   51 57A 68GLU 
   57 63N 74ASP 
   58 T 75ILE 
   60 66HIS 77LEU 
   72 78HIS 89VAL 
   73 79VAL 90ILE 
   89 A 106THR 
   90 A 107SER 
   102 108THR G 
   103 109ASP V 
   105 111PRO K 
   106 112MET D 
   133 139MET S 
   138 144GLU S 
   139 145LEU R 
   142 148LEU E 
   143 149VAL I 
   
93 
 
171 179GLU K 
   172 180GLY T  
   204 E 249GLN 
   207 F 252TYR 
   208 S 253LYS 
   212 R 257ILE 
   217 T 262VAL 
   248 F 293HIS 
   263 V 308PHE 
   264 L 309ASN 
   310 323PHE L 
   311 K 360ASP 
   335 348GLU K 
   336 349MET F 
   337 350VAL L 
   367 G 428ARG 
   368 R 429GLN 
   






List of Sequences for Knock-in variant 
design  
    In Pymol aligned the 1EFU & 1F60 structures, identified those sites that  
   were within 5 Angstroms of the opposite nucleotide exchange factor, and  
   selected those with the highest statistical support 
   
 




# Type I (Gu 99 & 01) & Type II Type I (Gu99 &01) & Type II 
 
DIVERGE Results 
16 H 18SER 
 
Color PP 
21 L 23THR 
 
  100-90 
37 A 54PHE 
 
  89-80 
38 R 55LYS 
   39 A 56TYR 
 
Type II Diverge 
40 F 57ALA 
 
  
 41 D 58TRP 
   43 I 60LEU 
 
Other Residue 
47 P 64LYS 
 
  
 51 A 68GLU 
   58 64THR I 
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60 66HIS L 
   62 68GLU K 
   72 78HIS V 
   73 79VAL I 
   89 95ALA T  
   98 V 115ILE 
   103 D 120VAL 
   105 P 129LYS 
   106 M 130ASP 
   138 E 163SER 
   139 L 164ARG 
   141 E 166GLN 
   142 L 167GLU 
   145 M 170LYS 
   150 L 175PHE 
   153 Q 178LYS 
   154 Y 179VAL 
   166 A 193GLY 
   167 L 194TRP 
   169 A 196GLY 
   204 215GLU Q 
   248 261PHE H 
   250 263LYS E  
   259 272GLU D 
   299 312SER 346ASN 
   301 314ASP 348PRO 
   302 315GLU 349GLY 
   303 316GLY 350GLN 
   304 317GLY I 
   339 P 394SER 
   366 G 427MET 
   367 380GLY R 
   368 381ARG Q 
   371 394GLY A 
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